Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity (410 views visite)
Expert Opin Emerg Drugsexpert Opinion On Emerging Drugs (ISSN: 1472-8214), 2008 Jun; 13(2): 383-392.
Export to Esporta in BibTeX Export to Esporta in EndNote
Paper type Tipo di articolo: Journal Article,
Impact factor: 3.08, 5-year impact factor Impact factor a 5 anni: 2.388
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-46849121802&partnerID=40&md5=66ec8ad5bc5be6927aa0d5b777404759
Keywords Parole chiave: Antiobesity Drugs, Carbonic Anhydrase, Lipogenesis, Topiramate, Zonisamide, Acetazolamide, Adiponectin, Agouti Related Protein, Alpha Intermedin, Amphetamine, Antiobesity Agent, Bromocriptine, Carbonate Dehydratase Inhibitor, Cocaine, Dipeptidyl Peptidase Iv, Dipeptidyl Peptidase Iv Inhibitor, Ethoxzolamide, Fenfluramine, Ghrelin, Insulin, Leptin, Liraglutide, Melanocortin 4 Receptor, Methazolamide, Multivitamin, Neuropeptide Y, Octreotide, Phentermine, Phentermine Resin, Proopiomelanocortin, Rimonabant, Sibutramine, Tetrahydrolipstatin, Unindexed Drug, Abdominal Cramp, Blood Pressure, Clinical Trial, Constipation, Depression, Drug Effect, Drug Mechanism, Drug Research, Enzyme Inhibition, Fatigue, Feces Incontinence, Flatulence, Gastrointestinal Irritation, Human, Increased Appetite, Libido Disorder, Malaise, Metabolic Acidosis, Myopia, Nausea, Nephrolithiasis, Nonhuman, Paresthesia, Prophylaxis, Pulse Rate, Review, Side Effect, Skin Tingling, Sleep Disorder, Steatorrhea, Taste Disorder, Valvular Heart Disease, Weight Reduction, Xerostomia, Anti-Obesity Agents, Carbonic Anhydrase Inhibitors, Cytosol, Fructose, Isoxazoles, Mitochondria,
Affiliations Affiliazioni:
*** IBB - CNR ***
Istituto di Biostrutture e Bioimmagini-CNR, via Mezzocannone 16, 80134 Naples, Italy
Università degli Studi di Firenze, Laboratorio di Chimica Bioinorganica, Via della Lastruccia 3, I-50019 Sesto Fiorentino (Firenze), Italy
Universit degli Studi di Firenze, Laboratorio di Chimica Bioinorganica, Via della Lastruccia 3, I-50019 Sesto Fiorentino (Firenze), Italy
References Riferimenti:
Friedman, J.M., A war on obesity, not the obese (2003) Science, 299, pp. 856-85
Hill, J.O., Wyatt, H.R., Reed, G.W., Peters, J.C., Obesity and the environment: Where do we go from here? (2003) Science, 299, pp. 853-855
Ioannides-Demos, L.L., Proietto, J., Tonkin, A.M., McNeil, J.J., Safety of drug therapies used for weight loss and treatment of obesity (2006) Drug Saf, 29, pp. 277-302
Campfield, L.A., Smith, F.J., Burn, P., Strategies and potential molecular targets for obesity treatment (1998) Science, 280, pp. 1383-1387
http://www.iotf.org, International Obesity Task Force. Available from:, Last accessed 3 March 2008Ethan, M., Berke, M.D., Nancy, E., Morden, M.D., Medical management of obesity (2000) Am Fam Physician, 62, pp. 419-426
Lyznicki, J.M., Young, D.C., Riggs, J.A., Davis, R.M., Obesity: Assessment and management in primary care (2001) Am Fam Physician, 63, pp. 2185-2196
Despres, J.P., Lemieux, S., Lamarche, B., The insulin resistance-dyslipidemic syndrome: Contribution of visceral obesity and therapeutic implications (1995) Int J Obes Relat Metab Disord, 19 (SUPPL. L), pp. S76-S86
Van Gaal, L., Mertens, I., Effects of obesity on cardiovascular systems and blood pressure control, digestive disease and cancer (1998) Clinical obesity, pp. 205-225. , Kopelman P, editor, Oxford: Blackwell
Avenell, A., Broom, J., Brown, T.J., Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement (2004) Health Technol Assess, 8, pp. 1-182
Chaput, J.P., Tremblay, A., Current and novel approaches to the drug therapy of obesity (2006) Eur J Clin Pharmacol, 62, pp. 793-803
Cheetham, S.C., Jackson, H.C., Vickers, S.P., Novel targets for the treatment of obesity: A review of progress (2004) Drug Discov Today Ther Strateg, 1, pp. 227-235
Bays, H., Dujovne, C., Pharmacotherapy of obesity: Currently marketed and upcoming agents (2002) Am J Cardiovasc Drugs, 2, pp. 245-253
Weintraub, M., Long-term weight control study: Conclusions (1992) Clin Pharmacol Ther, 51, pp. 642-646
Connolly, H.M., Crary, J.L., McGoon, M.D., Valvular heart disease associated with fenfluraminephentermine (1997) N Engl J Med, 337, pp. 581-588
McNelly, W., Goa, K.L., Sibutramine. A review of its contribution to the management of obesity (1998) Drugs, 56, pp. 1093-1124
Uscombe, G.P., Hopcroft, R.H., Thomas, P.C., Buckett, W.R., The contribution of metabolites to the rapid and potent down regulation of rat cortical beta adrenoreceptors by the putative antidepressant sibutramine hydrochloride (1989) Neuropharmacology, 28, pp. 129-134
Bray, G.A., Blackburn, G.L., Ferguson, J.M., Sibutramine produces dose-related weight loss (1999) Obes Res, 7, pp. 189-198
James, W.P., Astrup, A., Finer, N., Effect of sibutramine on weight maintenance after weight loss: A randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance (2000) Lancet, 356, pp. 2119-2125
Padwal, R.S., Majumdar, S.R., Drug treatments for obesity: Orlistat, sibutramine, and rimonabant (2007) Lancet, 369, pp. 71-77
Sidhaye, A., Cheskin, L.J., Pharmacologic treatment of obesity (2006) Adv Psychosom Med, 27, pp. 42-52
Davidson, M.H., Hauptman, J., DiGirolamo, M., Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat (1999) JAMA, 281, pp. 235-242
Hollander, P.A., Elbein, S.C., Hirsch, I.B., Role of orlistat in the treatment of obese patients with type 2 diabetes (1998) Diabetes Care, 21, pp. 1288-1294
Sjöström, L., Rissanen, A., Andersen, T., Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group (1998) Lancet, 352, pp. 167-172
Mittendorfer, B., Ostlund Jr, R.E., Patterson, B.W., Klein, S., Orlistat inhibits dietary cholesterol absorption (2001) Obes Res, 9, pp. 599-604
Heymsfield, S.B., Segal, K.R., Hauptman, J., Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults (2000) Arch Intern Med, 160, pp. 1321-1326
Kelley, D.E., Bray, G.A., Pi-Sunyer, F.X., Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1 year randomized controlled trial (2002) Diabetes Care, 25, pp. 1033-1041
Lindgärde, F., The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity Study (2000) J Intern Med, 248, pp. 245-254
Rössner, S., Sjöström, L., Noack, R., Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group (2000) Obes Res, 8, pp. 49-61
Gadde, K.M., Endocannabinoid receptor antagonists and other emerging pharmacological strategies for weight reduction (2005) Curr Drug Targets Cardiovasc Haematol Disord, 5, pp. 549-556
Pi-Sunyer, F.X., Aronne, L.J., Heshmati, H.M., Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial (2006) JAMA, 295, pp. 761-775. , for the RIO-North America Study Group
Bray, G.A., Ryan, D.H., Drug treatment of the overweight patient (2007) Gastroeneterology, 132, pp. 2239-2252
Rucker, D., Padwall, R., LI, S.K., Long term pharmacotherapy for obesity and overweight: Updated meta-analysis (2007) BMJ, 335, pp. 1194-1199
Bays, H.E., Current and investigational antiobesity agents and obesity therapeutic treatment targets (2004) Obes Res, 12, pp. 1197-1211
Obici, S., Feng, Z., Arduini, A., Inhibition of hypothalamic carnitine palmitoyltransferase-1 decreases food intake and glucose production (2003) Nat Med, 9, pp. 756-761
Supuran, C.T., Scozzafava, A., Casini, A., Carbonic anhydrase inhibitors (2003) Med Res Rev, 23, pp. 146-189
Supuran, C.T., Carbonic anhydrase inhibitors in the treatment and prophylaxis of obesity (2003) Expert Opin Ther Patents, 13, pp. 1545-1550
Tripp, B.C., Smith, K., Ferry, J.G., Carbonic anhydrase: New insights for an ancient enzyme (2001) J Biol Chem, 276, pp. 48615-48618
(2004) Carbonic anhydrase: Its inhibitors and activators, , Supuran CT, Scozzafava A, Conway J, editors, Boca Raton, FL: CRC Press
Dodgson, S.J., Inhibition of mitochondrial carbonic anhydrase: A discrepancy examined (1987) J Appl Physiol, 63, pp. 2134-2141
Dodgson, S.J., Cherian, K., Mitochondrial carbonic anhydrase is involved in rat renal glucose synthesis (1989) Am J Physiol, 257, pp. E791-E796
Spencer, I.M., Hargreaves, I., Chegwidden, W.R., Effect of the carbonic anhydrase inhibitor acetazolamide on lipid synthesis in the locust (1988) Biochem Soc Trans, 16, pp. 973-974
Chegwidden, W.R., Spencer, I.M., Carbonic anhydrase provides bicarbonate for de novo lipogenesis in the locus (1996) Comp Biochem Physiol, 115 B, pp. 247-254
Chegwidden, W.R., Dodgson, S.J., Spencer, I.M., The roles of carbonic anhydrase in metabolism, cell growth and cancer in animals (2000) The carbonic anhydrases, pp. 343-363. , Chegwidden WR, Edwards Y, Carter N, editors, new horizons. Birkhäuser, Basel
Lynch, C.J., Fox, H., Hazen, S.A., Role of hepatic carbonic anhydrase in de novo lipogenesis (1995) Biochem J, 310, pp. 197-202
Hazen, S.A., Waheed, A., Sly, W.S., Differentiation-dependent expression of CA V and the role of carbonic anhydrase isozymes in pyruvate carboxylation in adipocytes (1996) FASEB J, 10, pp. 481-490
Atwood, P.V., The structure and mechanism of action of pyruvate carboxylase (1995) Int J Biochem Cell Biol, 27, pp. 231-249
Alldred, J.B., Reilly, K.E., Short-term regulation of acetyl CoA carboxylase in tissues of higher animals (1997) Prog Lipid Res, 35, pp. 371-385
Forster, R.E., Dodgson, S.J., Membrane transport and provision of substrates for carbonic anhydrase in vertebrates (2000) The carbonic anhydrases, pp. 263-280. , Chegwidden WR, Edwards Y, Carter N, editors, new horizons. Birkhäuser Verlag, Basel
Parkkila, S., An overview of the distribution and function of carbonic anhydrase isozymes in mammals (2000) The carbonic anhydrases, pp. 79-94. , Chegwidden WR, Edwards Y, Carter N, editors, new horizons, Birkhäuser Verlag, Basel
Parkkila, S., Parkkila, A.K., Kivelä, J., Role of carbonic anhydrase and its inhibitors in biological science related to gastroenterology, neurology and nephrology (2000) The carbonic anhydrases, pp. 283-301. , Chegwidden WR, Edwards Y, Carter N, editors, new horizons. Birkhäuser, Basel
Bartlett, J.D., Jaanus, S.D., (1989) Clinical ocular pharmacology, , Boston, MA: Butterworth
Maren, T.H., Role of carbonic anhydrase in aqueous humor and cerebrospinal fluid formation (1992) Barriers and fluids of the eye and brain, pp. 37-48. , Segal MB, editor, London: MacMillan Press
Maren, T.H., The development of topical carbonic anhydrase inhibitors (1995) J Glaucoma, 4, pp. 49-62
Maren, T.H., Carbonic anhydrase: Chemistry, physiology and inhibition (1967) Physiol Rev, 47, pp. 595-781
Shank, R.P., Gardocki, J.F., Vaught, J.L., Topiramate: Preclinical evaluation of structurally novel anticonvulsant (1994) Epilepsia, 35, pp. 450-460
Edmonds, H.L., Jiang, Y.D., Zhang, P.Y., Shank, R.P., Anticonvulsant activity of topiramate and phenytoin in a rat model of ischemia-induced epilepsy (1996) Life Sci, 59, pp. PL127-PL131
Stringer, J.L., A comparison of topiramate and acetazolamide on seizure duration and paired-pulse inhibition in the dentate gyrus of the rat (2000) Epilepsy Res, 40, pp. 147-153
Sabers, A., Gram, L., Newer anticonvulsants: Comparative review of drug interactions and adverse effects (2000) Drugs, 60, pp. 23-33
Bourgeois, B.F.D., Pharmacokinetics and pharmacodynamics of topiramate (2000) J Child Neurol, 15, pp. S27-S30
Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: summary of the Fifth Eilat Conference. Epilepsy Res 2001
43:11-58Gordon, A., Price, L.H., Mood stabilization and weight loss with topiramate (1999) Am J Psychiatry, 156, pp. 968-969
Picard, F., Deshaies, Y., Lalonde, J., Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats (2000) Obes Res, 8, pp. 656-663
Mancini, M.C., Halpern, A., Investigational therapies in the treatment of obesity (2006) Expert Opin Investig Drugs, 15, pp. 897-915
Casini, A., Antel, J., Abbate, F., Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV (2003) Bioorg Med Chem Lett, 13, pp. 841-845
Chen, R.F., Kernohan, J.C., Combination of bovine carbonic anhydrase with a fluorescent sulfonamide (1967) J Biol Chem, 242, pp. 5813-5823
Vitale, R.M., Pedone, C., Amodeo, P., Carbonic anhydrase inhibitors: Molecular modeling study for the interaction of zonisamide and topiramate with isozyme va (2007) Bioorg Med Chem, 15, pp. 4152-4158
Zareba, G., Zonisamide: Review of its use in epilepsy therapy (2005) Drug Today (Barc), 41, pp. 589-597
Canitano, R., Clinical experience with topiramate to counteract neuroleptic induced weight gain in 10 individuals with autistic spectrum disorders (2005) Brain Dev, 27, pp. 228-232
Kim, C.S., Zonisamide effective for weight loss in women (2003) J Fam Pract, 52, pp. 600-601
Gadde, K.M., Franciscy, D.M., Wagner 2nd, H.R., Krishnan, K.R., Zonisamide for weight loss in obese adults: A randomized controlled trial (2003) JAMA, 289, pp. 1820-1825
De Simone, G., Di Fiore, A., Menchise, V., Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: Solution and X-ray crystallographic studies (2005) Bioorg Med Chem Lett, 15, pp. 2315-2320
Masuda, Y., Karasawa, T., Inhibitory effect of zonisamide on human carbonic anhydrase in vitro (1993) Arzneimittelforschung, 43, pp. 416-418
Friedman, J. M., A war on obesity, not the obese (2003) Science, 299, pp. 856-85
Hill, J. O., Wyatt, H. R., Reed, G. W., Peters, J. C., Obesity and the environment: Where do we go from here? (2003) Science, 299, pp. 853-855
Ioannides-Demos, L. L., Proietto, J., Tonkin, A. M., McNeil, J. J., Safety of drug therapies used for weight loss and treatment of obesity (2006) Drug Saf, 29, pp. 277-302
Campfield, L. A., Smith, F. J., Burn, P., Strategies and potential molecular targets for obesity treatment (1998) Science, 280, pp. 1383-1387
http: //www. iotf. org, International Obesity Task Force. Available from:, Last accessed 3 March 2008Ethan, M., Berke, M. D., Nancy, E., Morden, M. D., Medical management of obesity (2000) Am Fam Physician, 62, pp. 419-426
Lyznicki, J. M., Young, D. C., Riggs, J. A., Davis, R. M., Obesity: Assessment and management in primary care (2001) Am Fam Physician, 63, pp. 2185-2196
Despres, J. P., Lemieux, S., Lamarche, B., The insulin resistance-dyslipidemic syndrome: Contribution of visceral obesity and therapeutic implications (1995) Int J Obes Relat Metab Disord, 19 (SUPPL. L), pp. S76-S86
Chaput, J. P., Tremblay, A., Current and novel approaches to the drug therapy of obesity (2006) Eur J Clin Pharmacol, 62, pp. 793-803
Cheetham, S. C., Jackson, H. C., Vickers, S. P., Novel targets for the treatment of obesity: A review of progress (2004) Drug Discov Today Ther Strateg, 1, pp. 227-235
Connolly, H. M., Crary, J. L., McGoon, M. D., Valvular heart disease associated with fenfluraminephentermine (1997) N Engl J Med, 337, pp. 581-588
Uscombe, G. P., Hopcroft, R. H., Thomas, P. C., Buckett, W. R., The contribution of metabolites to the rapid and potent down regulation of rat cortical beta adrenoreceptors by the putative antidepressant sibutramine hydrochloride (1989) Neuropharmacology, 28, pp. 129-134
Bray, G. A., Blackburn, G. L., Ferguson, J. M., Sibutramine produces dose-related weight loss (1999) Obes Res, 7, pp. 189-198
James, W. P., Astrup, A., Finer, N., Effect of sibutramine on weight maintenance after weight loss: A randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance (2000) Lancet, 356, pp. 2119-2125
Padwal, R. S., Majumdar, S. R., Drug treatments for obesity: Orlistat, sibutramine, and rimonabant (2007) Lancet, 369, pp. 71-77
Davidson, M. H., Hauptman, J., DiGirolamo, M., Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat (1999) JAMA, 281, pp. 235-242
Hollander, P. A., Elbein, S. C., Hirsch, I. B., Role of orlistat in the treatment of obese patients with type 2 diabetes (1998) Diabetes Care, 21, pp. 1288-1294
Sj str m, L., Rissanen, A., Andersen, T., Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group (1998) Lancet, 352, pp. 167-172
Heymsfield, S. B., Segal, K. R., Hauptman, J., Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults (2000) Arch Intern Med, 160, pp. 1321-1326
Kelley, D. E., Bray, G. A., Pi-Sunyer, F. X., Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1 year randomized controlled trial (2002) Diabetes Care, 25, pp. 1033-1041
Lindg rde, F., The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity Study (2000) J Intern Med, 248, pp. 245-254
R ssner, S., Sj str m, L., Noack, R., Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group (2000) Obes Res, 8, pp. 49-61
Gadde, K. M., Endocannabinoid receptor antagonists and other emerging pharmacological strategies for weight reduction (2005) Curr Drug Targets Cardiovasc Haematol Disord, 5, pp. 549-556
Pi-Sunyer, F. X., Aronne, L. J., Heshmati, H. M., Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial (2006) JAMA, 295, pp. 761-775. , for the RIO-North America Study Group
Bray, G. A., Ryan, D. H., Drug treatment of the overweight patient (2007) Gastroeneterology, 132, pp. 2239-2252
Bays, H. E., Current and investigational antiobesity agents and obesity therapeutic treatment targets (2004) Obes Res, 12, pp. 1197-1211
Supuran, C. T., Scozzafava, A., Casini, A., Carbonic anhydrase inhibitors (2003) Med Res Rev, 23, pp. 146-189
Supuran, C. T., Carbonic anhydrase inhibitors in the treatment and prophylaxis of obesity (2003) Expert Opin Ther Patents, 13, pp. 1545-1550
Tripp, B. C., Smith, K., Ferry, J. G., Carbonic anhydrase: New insights for an ancient enzyme (2001) J Biol Chem, 276, pp. 48615-48618
(2004) Carbonic anhydrase: Its inhibitors and activators, , Supuran CT, Scozzafava A, Conway J, editors, Boca Raton, FL: CRC Press
Dodgson, S. J., Inhibition of mitochondrial carbonic anhydrase: A discrepancy examined (1987) J Appl Physiol, 63, pp. 2134-2141
Dodgson, S. J., Cherian, K., Mitochondrial carbonic anhydrase is involved in rat renal glucose synthesis (1989) Am J Physiol, 257, pp. E791-E796
Spencer, I. M., Hargreaves, I., Chegwidden, W. R., Effect of the carbonic anhydrase inhibitor acetazolamide on lipid synthesis in the locust (1988) Biochem Soc Trans, 16, pp. 973-974
Chegwidden, W. R., Spencer, I. M., Carbonic anhydrase provides bicarbonate for de novo lipogenesis in the locus (1996) Comp Biochem Physiol, 115 B, pp. 247-254
Chegwidden, W. R., Dodgson, S. J., Spencer, I. M., The roles of carbonic anhydrase in metabolism, cell growth and cancer in animals (2000) The carbonic anhydrases, pp. 343-363. , Chegwidden WR, Edwards Y, Carter N, editors, new horizons. Birkh user, Basel
Lynch, C. J., Fox, H., Hazen, S. A., Role of hepatic carbonic anhydrase in de novo lipogenesis (1995) Biochem J, 310, pp. 197-202
Hazen, S. A., Waheed, A., Sly, W. S., Differentiation-dependent expression of CA V and the role of carbonic anhydrase isozymes in pyruvate carboxylation in adipocytes (1996) FASEB J, 10, pp. 481-490
Atwood, P. V., The structure and mechanism of action of pyruvate carboxylase (1995) Int J Biochem Cell Biol, 27, pp. 231-249
Alldred, J. B., Reilly, K. E., Short-term regulation of acetyl CoA carboxylase in tissues of higher animals (1997) Prog Lipid Res, 35, pp. 371-385
Forster, R. E., Dodgson, S. J., Membrane transport and provision of substrates for carbonic anhydrase in vertebrates (2000) The carbonic anhydrases, pp. 263-280. , Chegwidden WR, Edwards Y, Carter N, editors, new horizons. Birkh user Verlag, Basel
Bartlett, J. D., Jaanus, S. D., (1989) Clinical ocular pharmacology, , Boston, MA: Butterworth
Maren, T. H., Role of carbonic anhydrase in aqueous humor and cerebrospinal fluid formation (1992) Barriers and fluids of the eye and brain, pp. 37-48. , Segal MB, editor, London: MacMillan Press
Maren, T. H., The development of topical carbonic anhydrase inhibitors (1995) J Glaucoma, 4, pp. 49-62
Maren, T. H., Carbonic anhydrase: Chemistry, physiology and inhibition (1967) Physiol Rev, 47, pp. 595-781
Shank, R. P., Gardocki, J. F., Vaught, J. L., Topiramate: Preclinical evaluation of structurally novel anticonvulsant (1994) Epilepsia, 35, pp. 450-460
Edmonds, H. L., Jiang, Y. D., Zhang, P. Y., Shank, R. P., Anticonvulsant activity of topiramate and phenytoin in a rat model of ischemia-induced epilepsy (1996) Life Sci, 59, pp. PL127-PL131
Stringer, J. L., A comparison of topiramate and acetazolamide on seizure duration and paired-pulse inhibition in the dentate gyrus of the rat (2000) Epilepsy Res, 40, pp. 147-153
Bourgeois, B. F. D., Pharmacokinetics and pharmacodynamics of topiramate (2000) J Child Neurol, 15, pp. S27-S30
43: 11-58Gordon, A., Price, L. H., Mood stabilization and weight loss with topiramate (1999) Am J Psychiatry, 156, pp. 968-969
Mancini, M. C., Halpern, A., Investigational therapies in the treatment of obesity (2006) Expert Opin Investig Drugs, 15, pp. 897-915
Chen, R. F., Kernohan, J. C., Combination of bovine carbonic anhydrase with a fluorescent sulfonamide (1967) J Biol Chem, 242, pp. 5813-5823
Vitale, R. M., Pedone, C., Amodeo, P., Carbonic anhydrase inhibitors: Molecular modeling study for the interaction of zonisamide and topiramate with isozyme va (2007) Bioorg Med Chem, 15, pp. 4152-4158
Kim, C. S., Zonisamide effective for weight loss in women (2003) J Fam Pract, 52, pp. 600-601
Gadde, K. M., Franciscy, D. M., Wagner 2nd, H. R., Krishnan, K. R., Zonisamide for weight loss in obese adults: A randomized controlled trial (2003) JAMA, 289, pp. 1820-1825
Expert Opin Emerg Drugsexpert Opinion On Emerging Drugs (ISSN: 1472-8214), 2008 Jun; 13(2): 383-392.
Export to Esporta in BibTeX Export to Esporta in EndNote
Paper type Tipo di articolo: Journal Article,
Impact factor: 3.08, 5-year impact factor Impact factor a 5 anni: 2.388
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-46849121802&partnerID=40&md5=66ec8ad5bc5be6927aa0d5b777404759
Keywords Parole chiave: Antiobesity Drugs, Carbonic Anhydrase, Lipogenesis, Topiramate, Zonisamide, Acetazolamide, Adiponectin, Agouti Related Protein, Alpha Intermedin, Amphetamine, Antiobesity Agent, Bromocriptine, Carbonate Dehydratase Inhibitor, Cocaine, Dipeptidyl Peptidase Iv, Dipeptidyl Peptidase Iv Inhibitor, Ethoxzolamide, Fenfluramine, Ghrelin, Insulin, Leptin, Liraglutide, Melanocortin 4 Receptor, Methazolamide, Multivitamin, Neuropeptide Y, Octreotide, Phentermine, Phentermine Resin, Proopiomelanocortin, Rimonabant, Sibutramine, Tetrahydrolipstatin, Unindexed Drug, Abdominal Cramp, Blood Pressure, Clinical Trial, Constipation, Depression, Drug Effect, Drug Mechanism, Drug Research, Enzyme Inhibition, Fatigue, Feces Incontinence, Flatulence, Gastrointestinal Irritation, Human, Increased Appetite, Libido Disorder, Malaise, Metabolic Acidosis, Myopia, Nausea, Nephrolithiasis, Nonhuman, Paresthesia, Prophylaxis, Pulse Rate, Review, Side Effect, Skin Tingling, Sleep Disorder, Steatorrhea, Taste Disorder, Valvular Heart Disease, Weight Reduction, Xerostomia, Anti-Obesity Agents, Carbonic Anhydrase Inhibitors, Cytosol, Fructose, Isoxazoles, Mitochondria,
Affiliations Affiliazioni:
*** IBB - CNR ***
Istituto di Biostrutture e Bioimmagini-CNR, via Mezzocannone 16, 80134 Naples, Italy
Università degli Studi di Firenze, Laboratorio di Chimica Bioinorganica, Via della Lastruccia 3, I-50019 Sesto Fiorentino (Firenze), Italy
Universit degli Studi di Firenze, Laboratorio di Chimica Bioinorganica, Via della Lastruccia 3, I-50019 Sesto Fiorentino (Firenze), Italy
References Riferimenti:
Friedman, J.M., A war on obesity, not the obese (2003) Science, 299, pp. 856-85
Hill, J.O., Wyatt, H.R., Reed, G.W., Peters, J.C., Obesity and the environment: Where do we go from here? (2003) Science, 299, pp. 853-855
Ioannides-Demos, L.L., Proietto, J., Tonkin, A.M., McNeil, J.J., Safety of drug therapies used for weight loss and treatment of obesity (2006) Drug Saf, 29, pp. 277-302
Campfield, L.A., Smith, F.J., Burn, P., Strategies and potential molecular targets for obesity treatment (1998) Science, 280, pp. 1383-1387
http://www.iotf.org, International Obesity Task Force. Available from:, Last accessed 3 March 2008Ethan, M., Berke, M.D., Nancy, E., Morden, M.D., Medical management of obesity (2000) Am Fam Physician, 62, pp. 419-426
Lyznicki, J.M., Young, D.C., Riggs, J.A., Davis, R.M., Obesity: Assessment and management in primary care (2001) Am Fam Physician, 63, pp. 2185-2196
Despres, J.P., Lemieux, S., Lamarche, B., The insulin resistance-dyslipidemic syndrome: Contribution of visceral obesity and therapeutic implications (1995) Int J Obes Relat Metab Disord, 19 (SUPPL. L), pp. S76-S86
Van Gaal, L., Mertens, I., Effects of obesity on cardiovascular systems and blood pressure control, digestive disease and cancer (1998) Clinical obesity, pp. 205-225. , Kopelman P, editor, Oxford: Blackwell
Avenell, A., Broom, J., Brown, T.J., Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement (2004) Health Technol Assess, 8, pp. 1-182
Chaput, J.P., Tremblay, A., Current and novel approaches to the drug therapy of obesity (2006) Eur J Clin Pharmacol, 62, pp. 793-803
Cheetham, S.C., Jackson, H.C., Vickers, S.P., Novel targets for the treatment of obesity: A review of progress (2004) Drug Discov Today Ther Strateg, 1, pp. 227-235
Bays, H., Dujovne, C., Pharmacotherapy of obesity: Currently marketed and upcoming agents (2002) Am J Cardiovasc Drugs, 2, pp. 245-253
Weintraub, M., Long-term weight control study: Conclusions (1992) Clin Pharmacol Ther, 51, pp. 642-646
Connolly, H.M., Crary, J.L., McGoon, M.D., Valvular heart disease associated with fenfluraminephentermine (1997) N Engl J Med, 337, pp. 581-588
McNelly, W., Goa, K.L., Sibutramine. A review of its contribution to the management of obesity (1998) Drugs, 56, pp. 1093-1124
Uscombe, G.P., Hopcroft, R.H., Thomas, P.C., Buckett, W.R., The contribution of metabolites to the rapid and potent down regulation of rat cortical beta adrenoreceptors by the putative antidepressant sibutramine hydrochloride (1989) Neuropharmacology, 28, pp. 129-134
Bray, G.A., Blackburn, G.L., Ferguson, J.M., Sibutramine produces dose-related weight loss (1999) Obes Res, 7, pp. 189-198
James, W.P., Astrup, A., Finer, N., Effect of sibutramine on weight maintenance after weight loss: A randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance (2000) Lancet, 356, pp. 2119-2125
Padwal, R.S., Majumdar, S.R., Drug treatments for obesity: Orlistat, sibutramine, and rimonabant (2007) Lancet, 369, pp. 71-77
Sidhaye, A., Cheskin, L.J., Pharmacologic treatment of obesity (2006) Adv Psychosom Med, 27, pp. 42-52
Davidson, M.H., Hauptman, J., DiGirolamo, M., Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat (1999) JAMA, 281, pp. 235-242
Hollander, P.A., Elbein, S.C., Hirsch, I.B., Role of orlistat in the treatment of obese patients with type 2 diabetes (1998) Diabetes Care, 21, pp. 1288-1294
Sjöström, L., Rissanen, A., Andersen, T., Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group (1998) Lancet, 352, pp. 167-172
Mittendorfer, B., Ostlund Jr, R.E., Patterson, B.W., Klein, S., Orlistat inhibits dietary cholesterol absorption (2001) Obes Res, 9, pp. 599-604
Heymsfield, S.B., Segal, K.R., Hauptman, J., Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults (2000) Arch Intern Med, 160, pp. 1321-1326
Kelley, D.E., Bray, G.A., Pi-Sunyer, F.X., Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1 year randomized controlled trial (2002) Diabetes Care, 25, pp. 1033-1041
Lindgärde, F., The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity Study (2000) J Intern Med, 248, pp. 245-254
Rössner, S., Sjöström, L., Noack, R., Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group (2000) Obes Res, 8, pp. 49-61
Gadde, K.M., Endocannabinoid receptor antagonists and other emerging pharmacological strategies for weight reduction (2005) Curr Drug Targets Cardiovasc Haematol Disord, 5, pp. 549-556
Pi-Sunyer, F.X., Aronne, L.J., Heshmati, H.M., Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial (2006) JAMA, 295, pp. 761-775. , for the RIO-North America Study Group
Bray, G.A., Ryan, D.H., Drug treatment of the overweight patient (2007) Gastroeneterology, 132, pp. 2239-2252
Rucker, D., Padwall, R., LI, S.K., Long term pharmacotherapy for obesity and overweight: Updated meta-analysis (2007) BMJ, 335, pp. 1194-1199
Bays, H.E., Current and investigational antiobesity agents and obesity therapeutic treatment targets (2004) Obes Res, 12, pp. 1197-1211
Obici, S., Feng, Z., Arduini, A., Inhibition of hypothalamic carnitine palmitoyltransferase-1 decreases food intake and glucose production (2003) Nat Med, 9, pp. 756-761
Supuran, C.T., Scozzafava, A., Casini, A., Carbonic anhydrase inhibitors (2003) Med Res Rev, 23, pp. 146-189
Supuran, C.T., Carbonic anhydrase inhibitors in the treatment and prophylaxis of obesity (2003) Expert Opin Ther Patents, 13, pp. 1545-1550
Tripp, B.C., Smith, K., Ferry, J.G., Carbonic anhydrase: New insights for an ancient enzyme (2001) J Biol Chem, 276, pp. 48615-48618
(2004) Carbonic anhydrase: Its inhibitors and activators, , Supuran CT, Scozzafava A, Conway J, editors, Boca Raton, FL: CRC Press
Dodgson, S.J., Inhibition of mitochondrial carbonic anhydrase: A discrepancy examined (1987) J Appl Physiol, 63, pp. 2134-2141
Dodgson, S.J., Cherian, K., Mitochondrial carbonic anhydrase is involved in rat renal glucose synthesis (1989) Am J Physiol, 257, pp. E791-E796
Spencer, I.M., Hargreaves, I., Chegwidden, W.R., Effect of the carbonic anhydrase inhibitor acetazolamide on lipid synthesis in the locust (1988) Biochem Soc Trans, 16, pp. 973-974
Chegwidden, W.R., Spencer, I.M., Carbonic anhydrase provides bicarbonate for de novo lipogenesis in the locus (1996) Comp Biochem Physiol, 115 B, pp. 247-254
Chegwidden, W.R., Dodgson, S.J., Spencer, I.M., The roles of carbonic anhydrase in metabolism, cell growth and cancer in animals (2000) The carbonic anhydrases, pp. 343-363. , Chegwidden WR, Edwards Y, Carter N, editors, new horizons. Birkhäuser, Basel
Lynch, C.J., Fox, H., Hazen, S.A., Role of hepatic carbonic anhydrase in de novo lipogenesis (1995) Biochem J, 310, pp. 197-202
Hazen, S.A., Waheed, A., Sly, W.S., Differentiation-dependent expression of CA V and the role of carbonic anhydrase isozymes in pyruvate carboxylation in adipocytes (1996) FASEB J, 10, pp. 481-490
Atwood, P.V., The structure and mechanism of action of pyruvate carboxylase (1995) Int J Biochem Cell Biol, 27, pp. 231-249
Alldred, J.B., Reilly, K.E., Short-term regulation of acetyl CoA carboxylase in tissues of higher animals (1997) Prog Lipid Res, 35, pp. 371-385
Forster, R.E., Dodgson, S.J., Membrane transport and provision of substrates for carbonic anhydrase in vertebrates (2000) The carbonic anhydrases, pp. 263-280. , Chegwidden WR, Edwards Y, Carter N, editors, new horizons. Birkhäuser Verlag, Basel
Parkkila, S., An overview of the distribution and function of carbonic anhydrase isozymes in mammals (2000) The carbonic anhydrases, pp. 79-94. , Chegwidden WR, Edwards Y, Carter N, editors, new horizons, Birkhäuser Verlag, Basel
Parkkila, S., Parkkila, A.K., Kivelä, J., Role of carbonic anhydrase and its inhibitors in biological science related to gastroenterology, neurology and nephrology (2000) The carbonic anhydrases, pp. 283-301. , Chegwidden WR, Edwards Y, Carter N, editors, new horizons. Birkhäuser, Basel
Bartlett, J.D., Jaanus, S.D., (1989) Clinical ocular pharmacology, , Boston, MA: Butterworth
Maren, T.H., Role of carbonic anhydrase in aqueous humor and cerebrospinal fluid formation (1992) Barriers and fluids of the eye and brain, pp. 37-48. , Segal MB, editor, London: MacMillan Press
Maren, T.H., The development of topical carbonic anhydrase inhibitors (1995) J Glaucoma, 4, pp. 49-62
Maren, T.H., Carbonic anhydrase: Chemistry, physiology and inhibition (1967) Physiol Rev, 47, pp. 595-781
Shank, R.P., Gardocki, J.F., Vaught, J.L., Topiramate: Preclinical evaluation of structurally novel anticonvulsant (1994) Epilepsia, 35, pp. 450-460
Edmonds, H.L., Jiang, Y.D., Zhang, P.Y., Shank, R.P., Anticonvulsant activity of topiramate and phenytoin in a rat model of ischemia-induced epilepsy (1996) Life Sci, 59, pp. PL127-PL131
Stringer, J.L., A comparison of topiramate and acetazolamide on seizure duration and paired-pulse inhibition in the dentate gyrus of the rat (2000) Epilepsy Res, 40, pp. 147-153
Sabers, A., Gram, L., Newer anticonvulsants: Comparative review of drug interactions and adverse effects (2000) Drugs, 60, pp. 23-33
Bourgeois, B.F.D., Pharmacokinetics and pharmacodynamics of topiramate (2000) J Child Neurol, 15, pp. S27-S30
Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: summary of the Fifth Eilat Conference. Epilepsy Res 2001
43:11-58Gordon, A., Price, L.H., Mood stabilization and weight loss with topiramate (1999) Am J Psychiatry, 156, pp. 968-969
Picard, F., Deshaies, Y., Lalonde, J., Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats (2000) Obes Res, 8, pp. 656-663
Mancini, M.C., Halpern, A., Investigational therapies in the treatment of obesity (2006) Expert Opin Investig Drugs, 15, pp. 897-915
Casini, A., Antel, J., Abbate, F., Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV (2003) Bioorg Med Chem Lett, 13, pp. 841-845
Chen, R.F., Kernohan, J.C., Combination of bovine carbonic anhydrase with a fluorescent sulfonamide (1967) J Biol Chem, 242, pp. 5813-5823
Vitale, R.M., Pedone, C., Amodeo, P., Carbonic anhydrase inhibitors: Molecular modeling study for the interaction of zonisamide and topiramate with isozyme va (2007) Bioorg Med Chem, 15, pp. 4152-4158
Zareba, G., Zonisamide: Review of its use in epilepsy therapy (2005) Drug Today (Barc), 41, pp. 589-597
Canitano, R., Clinical experience with topiramate to counteract neuroleptic induced weight gain in 10 individuals with autistic spectrum disorders (2005) Brain Dev, 27, pp. 228-232
Kim, C.S., Zonisamide effective for weight loss in women (2003) J Fam Pract, 52, pp. 600-601
Gadde, K.M., Franciscy, D.M., Wagner 2nd, H.R., Krishnan, K.R., Zonisamide for weight loss in obese adults: A randomized controlled trial (2003) JAMA, 289, pp. 1820-1825
De Simone, G., Di Fiore, A., Menchise, V., Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: Solution and X-ray crystallographic studies (2005) Bioorg Med Chem Lett, 15, pp. 2315-2320
Masuda, Y., Karasawa, T., Inhibitory effect of zonisamide on human carbonic anhydrase in vitro (1993) Arzneimittelforschung, 43, pp. 416-418
Friedman, J. M., A war on obesity, not the obese (2003) Science, 299, pp. 856-85
Hill, J. O., Wyatt, H. R., Reed, G. W., Peters, J. C., Obesity and the environment: Where do we go from here? (2003) Science, 299, pp. 853-855
Ioannides-Demos, L. L., Proietto, J., Tonkin, A. M., McNeil, J. J., Safety of drug therapies used for weight loss and treatment of obesity (2006) Drug Saf, 29, pp. 277-302
Campfield, L. A., Smith, F. J., Burn, P., Strategies and potential molecular targets for obesity treatment (1998) Science, 280, pp. 1383-1387
http: //www. iotf. org, International Obesity Task Force. Available from:, Last accessed 3 March 2008Ethan, M., Berke, M. D., Nancy, E., Morden, M. D., Medical management of obesity (2000) Am Fam Physician, 62, pp. 419-426
Lyznicki, J. M., Young, D. C., Riggs, J. A., Davis, R. M., Obesity: Assessment and management in primary care (2001) Am Fam Physician, 63, pp. 2185-2196
Despres, J. P., Lemieux, S., Lamarche, B., The insulin resistance-dyslipidemic syndrome: Contribution of visceral obesity and therapeutic implications (1995) Int J Obes Relat Metab Disord, 19 (SUPPL. L), pp. S76-S86
Chaput, J. P., Tremblay, A., Current and novel approaches to the drug therapy of obesity (2006) Eur J Clin Pharmacol, 62, pp. 793-803
Cheetham, S. C., Jackson, H. C., Vickers, S. P., Novel targets for the treatment of obesity: A review of progress (2004) Drug Discov Today Ther Strateg, 1, pp. 227-235
Connolly, H. M., Crary, J. L., McGoon, M. D., Valvular heart disease associated with fenfluraminephentermine (1997) N Engl J Med, 337, pp. 581-588
Uscombe, G. P., Hopcroft, R. H., Thomas, P. C., Buckett, W. R., The contribution of metabolites to the rapid and potent down regulation of rat cortical beta adrenoreceptors by the putative antidepressant sibutramine hydrochloride (1989) Neuropharmacology, 28, pp. 129-134
Bray, G. A., Blackburn, G. L., Ferguson, J. M., Sibutramine produces dose-related weight loss (1999) Obes Res, 7, pp. 189-198
James, W. P., Astrup, A., Finer, N., Effect of sibutramine on weight maintenance after weight loss: A randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance (2000) Lancet, 356, pp. 2119-2125
Padwal, R. S., Majumdar, S. R., Drug treatments for obesity: Orlistat, sibutramine, and rimonabant (2007) Lancet, 369, pp. 71-77
Davidson, M. H., Hauptman, J., DiGirolamo, M., Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat (1999) JAMA, 281, pp. 235-242
Hollander, P. A., Elbein, S. C., Hirsch, I. B., Role of orlistat in the treatment of obese patients with type 2 diabetes (1998) Diabetes Care, 21, pp. 1288-1294
Sj str m, L., Rissanen, A., Andersen, T., Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group (1998) Lancet, 352, pp. 167-172
Heymsfield, S. B., Segal, K. R., Hauptman, J., Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults (2000) Arch Intern Med, 160, pp. 1321-1326
Kelley, D. E., Bray, G. A., Pi-Sunyer, F. X., Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1 year randomized controlled trial (2002) Diabetes Care, 25, pp. 1033-1041
Lindg rde, F., The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity Study (2000) J Intern Med, 248, pp. 245-254
R ssner, S., Sj str m, L., Noack, R., Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group (2000) Obes Res, 8, pp. 49-61
Gadde, K. M., Endocannabinoid receptor antagonists and other emerging pharmacological strategies for weight reduction (2005) Curr Drug Targets Cardiovasc Haematol Disord, 5, pp. 549-556
Pi-Sunyer, F. X., Aronne, L. J., Heshmati, H. M., Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial (2006) JAMA, 295, pp. 761-775. , for the RIO-North America Study Group
Bray, G. A., Ryan, D. H., Drug treatment of the overweight patient (2007) Gastroeneterology, 132, pp. 2239-2252
Bays, H. E., Current and investigational antiobesity agents and obesity therapeutic treatment targets (2004) Obes Res, 12, pp. 1197-1211
Supuran, C. T., Scozzafava, A., Casini, A., Carbonic anhydrase inhibitors (2003) Med Res Rev, 23, pp. 146-189
Supuran, C. T., Carbonic anhydrase inhibitors in the treatment and prophylaxis of obesity (2003) Expert Opin Ther Patents, 13, pp. 1545-1550
Tripp, B. C., Smith, K., Ferry, J. G., Carbonic anhydrase: New insights for an ancient enzyme (2001) J Biol Chem, 276, pp. 48615-48618
(2004) Carbonic anhydrase: Its inhibitors and activators, , Supuran CT, Scozzafava A, Conway J, editors, Boca Raton, FL: CRC Press
Dodgson, S. J., Inhibition of mitochondrial carbonic anhydrase: A discrepancy examined (1987) J Appl Physiol, 63, pp. 2134-2141
Dodgson, S. J., Cherian, K., Mitochondrial carbonic anhydrase is involved in rat renal glucose synthesis (1989) Am J Physiol, 257, pp. E791-E796
Spencer, I. M., Hargreaves, I., Chegwidden, W. R., Effect of the carbonic anhydrase inhibitor acetazolamide on lipid synthesis in the locust (1988) Biochem Soc Trans, 16, pp. 973-974
Chegwidden, W. R., Spencer, I. M., Carbonic anhydrase provides bicarbonate for de novo lipogenesis in the locus (1996) Comp Biochem Physiol, 115 B, pp. 247-254
Chegwidden, W. R., Dodgson, S. J., Spencer, I. M., The roles of carbonic anhydrase in metabolism, cell growth and cancer in animals (2000) The carbonic anhydrases, pp. 343-363. , Chegwidden WR, Edwards Y, Carter N, editors, new horizons. Birkh user, Basel
Lynch, C. J., Fox, H., Hazen, S. A., Role of hepatic carbonic anhydrase in de novo lipogenesis (1995) Biochem J, 310, pp. 197-202
Hazen, S. A., Waheed, A., Sly, W. S., Differentiation-dependent expression of CA V and the role of carbonic anhydrase isozymes in pyruvate carboxylation in adipocytes (1996) FASEB J, 10, pp. 481-490
Atwood, P. V., The structure and mechanism of action of pyruvate carboxylase (1995) Int J Biochem Cell Biol, 27, pp. 231-249
Alldred, J. B., Reilly, K. E., Short-term regulation of acetyl CoA carboxylase in tissues of higher animals (1997) Prog Lipid Res, 35, pp. 371-385
Forster, R. E., Dodgson, S. J., Membrane transport and provision of substrates for carbonic anhydrase in vertebrates (2000) The carbonic anhydrases, pp. 263-280. , Chegwidden WR, Edwards Y, Carter N, editors, new horizons. Birkh user Verlag, Basel
Bartlett, J. D., Jaanus, S. D., (1989) Clinical ocular pharmacology, , Boston, MA: Butterworth
Maren, T. H., Role of carbonic anhydrase in aqueous humor and cerebrospinal fluid formation (1992) Barriers and fluids of the eye and brain, pp. 37-48. , Segal MB, editor, London: MacMillan Press
Maren, T. H., The development of topical carbonic anhydrase inhibitors (1995) J Glaucoma, 4, pp. 49-62
Maren, T. H., Carbonic anhydrase: Chemistry, physiology and inhibition (1967) Physiol Rev, 47, pp. 595-781
Shank, R. P., Gardocki, J. F., Vaught, J. L., Topiramate: Preclinical evaluation of structurally novel anticonvulsant (1994) Epilepsia, 35, pp. 450-460
Edmonds, H. L., Jiang, Y. D., Zhang, P. Y., Shank, R. P., Anticonvulsant activity of topiramate and phenytoin in a rat model of ischemia-induced epilepsy (1996) Life Sci, 59, pp. PL127-PL131
Stringer, J. L., A comparison of topiramate and acetazolamide on seizure duration and paired-pulse inhibition in the dentate gyrus of the rat (2000) Epilepsy Res, 40, pp. 147-153
Bourgeois, B. F. D., Pharmacokinetics and pharmacodynamics of topiramate (2000) J Child Neurol, 15, pp. S27-S30
43: 11-58Gordon, A., Price, L. H., Mood stabilization and weight loss with topiramate (1999) Am J Psychiatry, 156, pp. 968-969
Mancini, M. C., Halpern, A., Investigational therapies in the treatment of obesity (2006) Expert Opin Investig Drugs, 15, pp. 897-915
Chen, R. F., Kernohan, J. C., Combination of bovine carbonic anhydrase with a fluorescent sulfonamide (1967) J Biol Chem, 242, pp. 5813-5823
Vitale, R. M., Pedone, C., Amodeo, P., Carbonic anhydrase inhibitors: Molecular modeling study for the interaction of zonisamide and topiramate with isozyme va (2007) Bioorg Med Chem, 15, pp. 4152-4158
Kim, C. S., Zonisamide effective for weight loss in women (2003) J Fam Pract, 52, pp. 600-601
Gadde, K. M., Franciscy, D. M., Wagner 2nd, H. R., Krishnan, K. R., Zonisamide for weight loss in obese adults: A randomized controlled trial (2003) JAMA, 289, pp. 1820-1825
Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity
Background: Obesity is a widespread disease in both the developed and developing world. Few pharmacological approaches for its treatment exist at this time. Objective: This review summarises the currently approved obesity therapies and describes a possible new approach for the treatment and prophylaxis of this disease, based on the inhibition of carbonic anhydrases (CAs, EC 4.2.1.1), enzymes involved in several steps of de novo lipogenesis, both in the mitochondria and the cytosol of cells. Methods: Topiramate and zonisamide, two antiepileptic drugs showing strong CA inhibitory properties, have been reported as an example of this approach, as clinical data have shown that these compounds induce persistent weight loss in obese patients. Conclusions: The use of topiramate and zonisamide as lead molecules for the design of CA inhibitors targeting isozymes involved in lipogenesis could represent the beginning of a very promising new approach for the treatment of obesity. © 2008 Informa UK Ltd.
Background: Obesity is a widespread disease in both the developed and developing world. Few pharmacological approaches for its treatment exist at this time. Objective: This review summarises the currently approved obesity therapies and describes a possible new approach for the treatment and prophylaxis of this disease, based on the inhibition of carbonic anhydrases (CAs, EC 4.2.1.1), enzymes involved in several steps of de novo lipogenesis, both in the mitochondria and the cytosol of cells. Methods: Topiramate and zonisamide, two antiepileptic drugs showing strong CA inhibitory properties, have been reported as an example of this approach, as clinical data have shown that these compounds induce persistent weight loss in obese patients. Conclusions: The use of topiramate and zonisamide as lead molecules for the design of CA inhibitors targeting isozymes involved in lipogenesis could represent the beginning of a very promising new approach for the treatment of obesity. © 2008 Informa UK Ltd.
Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity
Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity
Urbański LJ, Angeli A, Hytönen VP, Di Fiore A, De Simone G, Parkkila S, Supuran CT
* Inhibition of the β-carbonic anhydrase from the protozoan pathogen Trichomonas vaginalis with sulphonamides (102 visite)
J Enzyme Inhib Med Chem (ISSN: 1475-6366linking), 2021 Dec; 36(1): 329-334.
Impact Factor: 4.673
Dettagli Esporta in BibTeX Esporta in EndNote
D’ambrosio K, Di Fiore A, Buonanno M, Kumari S, Tiwari M, Supuran CT, Mishra CB, Monti SM, De Simone G
* The crystal structures of 2-(4-benzhydrylpiperazin-1-yl)-N-(4-sulfamoylphenyl)acetamide in complex with human carbonic anhydrase II and VII provide insights into selective CA inhibitor development (53 visite)
New Journal Of Chemistry, 2021; 45: 147-152.
Impact Factor: 3.288
Dettagli Esporta in BibTeX Esporta in EndNote
Urbański LJ, Di Fiore A, Azizi L, Hytönen VP, Kuuslahti M, Buonanno M, Monti SM, Angeli A, Zolfaghari Emameh R, Supuran CT, De Simone G, Parkkila S
* Biochemical and structural characterisation of a protozoan beta-carbonic anhydrase from Trichomonas vaginalis (90 visite)
J Enzyme Inhib Med Chem (ISSN: 1475-6366linking), 2020 Dec; 35(1): 1292-1299.
Impact Factor: 4.673
Dettagli Esporta in BibTeX Esporta in EndNote
Di Fiore A, Supuran CT, Scaloni A, De Simone G
* Human carbonic anhydrases and post-translational modifications: a hidden world possibly affecting protein properties and functions (94 visite)
J Enzyme Inhib Med Chem (ISSN: 1475-6366linking), 2020 Dec; 35(1): 1450-1461.
Impact Factor: 4.673
Dettagli Esporta in BibTeX Esporta in EndNote
Urbański LJ, Angeli A, Hytönen VP, Di Fiore A, Parkkila S, De Simone G, Supuran CT
* Inhibition of the newly discovered β‑carbonic anhydrase from the protozoan pathogen Trichomonas vaginalis with inorganic anions and small molecules (54 visite)
J Inorg Biochem (ISSN: 0162-0134linking), 2020 Dec; 213: 111274-111274.
Impact Factor: 3.212
Dettagli Esporta in BibTeX Esporta in EndNote
Sarnella A, D'Avino G, Hill BS, Alterio V, Winum JY, Supuran CT, De Simone G, Zannetti A
* A Novel Inhibitor of Carbonic Anhydrases Prevents Hypoxia-Induced TNBC Cell Plasticity (41 visite) (PDF 12 visite)
Int J Mol Sci (ISSN: 1422-0067linking), 2020 Nov 9; 21(21): N/D-N/D.
Impact Factor: 4.556
Dettagli Esporta in BibTeX Esporta in EndNote
D'Ambrosio K, Carradori S, Cesa S, Angeli A, Monti SM, Supuran CT, De Simone G
* Catechols: a new class of carbonic anhydrase inhibitors (55 visite)
Chem Commun (ISSN: 1359-7345linking), 2020 Nov 4; 56(85): 13033-13033.
Impact Factor: 5.996
Dettagli Esporta in BibTeX Esporta in EndNote
Angeli A, Carta F, Nocentini A, Winum J, Zalubovskis R, Akdemir A, Onnis V, Eldehna WM, Capasso C, De Simone G, Monti Simona M, Carradori S, Donald WA, Dedhar S, Supuran CT
* Carbonic Anhydrase Inhibitors Targeting Metabolism and Tumor Microenvironment (56 visite)
Metabolites, 2020 Oct 14; 10: 412-412.
Impact Factor: 4.097
Dettagli Esporta in BibTeX Esporta in EndNote
Bozdag M, Supuran CT, Esposito D, Angeli A, Carta F, Monti SM, De Simone G, Alterio V
* 2-Mercaptobenzoxazoles: a class of carbonic anhydrase inhibitors with a novel binding mode to the enzyme active site (75 visite)
Chem Commun (ISSN: 1359-7345linking), 2020 Jul 23; 56(59): 8297-8300.
Impact Factor: 5.996
Dettagli Esporta in BibTeX Esporta in EndNote
Polito R, Costabile G, Nigro E, Giacco R, Vetrani C, Anniballi G, Luongo D, Riccardi G, Daniele A, Annuzzi G
* Nutritional factors influencing plasma adiponectin levels: results from a randomised controlled study with whole-grain cereals (142 visite) (PDF 70 visite)
Int J Food Sci Nutr (ISSN: 0963-7486linking), 2020 Jun; 71(4): 509-515.
Impact Factor: 1.451
Dettagli Esporta in BibTeX Esporta in EndNote
Nocentini A, Alterio V, Bua S, Micheli L, Esposito D, Buonanno M, Bartolucci G, Osman SM, Alothman ZA, Cirilli R, Pierini M, Monti SM, Di Cesare Mannelli L, Gratteri P, Ghelardini C, De Simone G, Supuran CT
* Phenyl(thio)phosphon(amid)ate Benzenesulfonamides as Potent and Selective Inhibitors of Human Carbonic Anhydrases II and VII Counteract Allodynia in a Mouse Model of Oxaliplatin-Induced Neuropathy (75 visite)
J Med Chem (ISSN: 0022-2623linking), 2020 May 28; 63(10): 5185-5200.
Impact Factor: 6.205
Dettagli Esporta in BibTeX Esporta in EndNote
Mancuso F, Di Fiore A, De Luca L, Angeli A, Monti SM, De Simone G, Supuran CT, Gitto R
* Looking toward the Rim of the Active Site Cavity of Druggable Human Carbonic Anhydrase Isoforms (73 visite)
Acs Med Chem Lett (ISSN: 1948-5875linking), 2020 May 14; 11(5): 1000-1005.
Impact Factor: 3.975
Dettagli Esporta in BibTeX Esporta in EndNote
Langella E, Buonanno M, De Simone G, Monti SM
* Intrinsically disordered features of carbonic anhydrase IX proteoglycan-like domain (57 visite)
Cell Mol Life Sci (ISSN: 1420-682xlinking), 2020; 21: 8405-8405.
Impact Factor: 6.496
Dettagli Esporta in BibTeX Esporta in EndNote
Alterio V, Kellner M, Esposito D, Liesche-starnecker F, Bua S, Supuran CT, Monti SM, Zeidler R, De Simone G
* Biochemical and structural insights into Carbonic Anhydrase XII/Fab6A10 complex (142 visite)
J Mol Biol (ISSN: 0022-2836linking, 1089-8638), 2019 Dec 6; 431(24): 4910-4921.
Impact Factor: 5.067
Dettagli Esporta in BibTeX Esporta in EndNote
De Simone G, Di Fiore A, Truppo E, Langella E, Vullo D, Supuran CT, Monti SM
* Exploration of the residues modulating the catalytic features of human carbonic anhydrase XIII by a site-specific mutagenesis approach (189 visite)
J Enzym Inhib Med Ch (ISSN: 1475-6366linking, 1475-6374electronic), 2019 Dec; 34(1): 1506-1510.
Impact Factor: 4.027
Dettagli Esporta in BibTeX Esporta in EndNote
Langella E, Alterio V, D'Ambrosio K, Cadoni R, Winum JY, Supuran CT, Monti SM, De Simone G, Di Fiore A
* Exploring benzoxaborole derivatives as carbonic anhydrase inhibitors: a structural and computational analysis reveals their conformational variability as a tool to increase enzyme selectivity (201 visite)
J Enzym Inhib Med Ch (ISSN: 1475-6366linking, 1475-6374electronic), 2019 Dec; 34(1): 1498-1505.
Impact Factor: 4.027
Dettagli Esporta in BibTeX Esporta in EndNote
Buemi MR, Di Fiore A, De Luca L, Angeli A, Mancuso F, Ferro S, Monti SM, Buonanno M, Russo E, De Sarro G, De Simone G, Supuran CT, Gitto R
* Exploring structural properties of potent human carbonic anhydrase inhibitors bearing a 4-(cycloalkylamino-1-carbonyl)benzenesulfonamide moiety (265 visite)
Eur J Med Chem (ISSN: 1768-3254electronic, 0223-5234linking), 2019 Feb 1; 163: 443-452.
Impact Factor: 4.833
Dettagli Esporta in BibTeX Esporta in EndNote
De Simone G
* Targeted treatment of anaerobic cancer. Patent evaluation of US2016279084 and US2017056350 (193 visite)
Expert Opin Ther Pat (ISSN: 1744-7674electronic, 1354-3776linking), 2019 Jan; 29(1): 1-6.
Impact Factor: 3.699
Dettagli Esporta in BibTeX Esporta in EndNote
Alterio V, Esposito D, Monti SM, Supuran CT, De Simone G
* Crystal structure of the human carbonic anhydrase II adduct with 1-(4-sulfamoylphenyl-ethyl)-2, 4, 6-triphenylpyridinium perchlorate, a membrane-impermeant, isoform selective inhibitor (498 visite)
J Enzym Inhib Med Ch (ISSN: 1475-6374electronic, 1475-6366linking), 2018 Dec; 33(1): 151-157.
Impact Factor: 4.293
Dettagli Esporta in BibTeX Esporta in EndNote
Monti SM, Meccariello A, Ceruso M, Szafranski K, Slawinski J, Supuran CT
* Inhibition studies of Brucella suis beta-carbonic anhydrases with a series of 4-substituted pyridine-3-sulphonamides (320 visite)
J Enzym Inhib Med Ch (ISSN: 1475-6374electronic, 1475-6366linking), 2018 Dec; 33(1): 255-259.
Impact Factor: 2.332
Dettagli Esporta in BibTeX Esporta in EndNote
Angeli A, Buonanno M, Donald WA, Monti SM, Supuran CT
* The zinc - but not cadmium - containing zeta-carbonic from the diatom Thalassiosira weissflogii is potently activated by amines and amino acids (136 visite)
Bioorg Chem (ISSN: 1090-2120electronic, 0045-2068linking), 2018 Oct; 80: 261-265.
Impact Factor: 3.929
Dettagli Esporta in BibTeX Esporta in EndNote
De Simone G, Angeli A, Bozdag M, Supuran CT, Winum JY, Monti SM, Alterio V
* Inhibition of carbonic anhydrases by a substrate analog: benzyl carbamate directly coordinates the catalytic zinc ion mimicking bicarbonate binding (218 visite)
Chem Commun (ISSN: 1364-548xelectronic, 1359-7345linking), 2018 Sep 11; 54(73): 10312-10315.
Impact Factor: 6.169
Dettagli Esporta in BibTeX Esporta in EndNote
Langella E, Buonanno M, Vullo D, Dathan N, Leone M, Supuran C, De Simone G, Monti SM
* Biochemical, biophysical and molecular dynamics studies on the proteoglycan-like domain of carbonic anhydrase IX (285 visite)
Cell Mol Life Sci (ISSN: 1420-682xlinking), 2018 Sep; 75(17): 3283-3296.
Impact Factor: 6.721
Dettagli Esporta in BibTeX Esporta in EndNote
Supuran CT, Alterio V, Di Fiore A, D'Ambrosio K, Carta F, Monti SM, De Simone G
* Inhibition of carbonic anhydrase IX targets primary tumors, metastases, and cancer stem cells: Three for the price of one (260 visite)
Med Res Rev (ISSN: 1098-1128electronic, 0198-6325linking), 2018 Sep; 38(6): 1799-1836.
Impact Factor: 8.29
Dettagli Esporta in BibTeX Esporta in EndNote
Mishra CB, Kumari S, Angeli A, Bua S, Buonanno M, Monti SM, Tiwari M, Supuran CT
* Discovery of potent anti-convulsant carbonic anhydrase inhibitors: Design, synthesis, in vitro and in vivo appraisal (203 visite)
Eur J Med Chem (ISSN: 0223-5234linking, 1768-3254electronic), 2018 Aug 5; 156: 430-443.
Impact Factor: 4.816
Dettagli Esporta in BibTeX Esporta in EndNote
Di Fiore A, Monti DM, Scaloni A, De Simone G, Monti SM
* Protective Role of Carbonic Anhydrases III and VII in Cellular Defense Mechanisms upon Redox Unbalance (183 visite)
Oxid Med Cell Longev (ISSN: 1942-0994linking), 2018 Aug 5; 2018:2018306: 2018306-2018306.
Impact Factor: 4.936
Dettagli Esporta in BibTeX Esporta in EndNote
Buonanno M, Di Fiore A, Langella E, D’ambrosio K, Supuran CT, Monti SM, De Simone G
* The Crystal Structure of a hCA VII Variant Provides Insights into the Molecular Determinants Responsible for Its Catalytic Behavior (225 visite)
Int J Mol Sc (ISSN: 1661-6596, 1422-0067, 1422-0067electronic), 2018 May; 19(6): 19-24.
Impact Factor: 3.687
Dettagli Esporta in BibTeX Esporta in EndNote
D'Ambrosio K, Supuran CT, De Simone G
* Are Carbonic Anhydrases Suitable Targets to Fight Protozoan Parasitic Diseases? (217 visite)
Curr Med Chem (ISSN: 1875-533xelectronic, 0929-8673linking), 2018; 25(39): 5266-5278.
Impact Factor: 4.63
Dettagli Esporta in BibTeX Esporta in EndNote
De Simone G, Langella E, Esposito D, Supuran CT, Monti SM, Winum JY, Alterio V
* Insights into the binding mode of sulphamates and sulphamides to hCA II: crystallographic studies and binding free energy calculations (218 visite)
J Enzym Inhib Med Ch (ISSN: 1475-6366, 1475-6374electronic, 1475-6366linking), 2017 Dec; 32(1): 1002-1011.
Impact Factor: 3.638
Dettagli Esporta in BibTeX Esporta in EndNote
Monti DM, De Simone G, Langella E, Supuran CT, Di Fiore A, Monti SM
* Insights into the role of reactive sulfhydryl groups of Carbonic Anhydrase III and VII during oxidative damage (326 visite)
J Enzym Inhib Med Ch (ISSN: 1475-6366, 1475-6374electronic, 1475-6366linking), 2017 Dec; 32(1): 5-12.
Impact Factor: 3.638
Dettagli Esporta in BibTeX Esporta in EndNote
Taskinen MR, Soderlund S, Bogl LH, Hakkarainen A, Matikainen N, Pietilainen KH, Rasanen S, Lundbom N, Bjornson E, Eliasson B, Mancina RM, Romeo S, Almeras N, Della Pepa G, Vetrani C, Prinster A, Annuzzi G, Rivellese A, Despres JP, Boren J
* Adverse effects of fructose on cardiometabolic risk factors and hepatic lipid metabolism in subjects with abdominal obesity (293 visite)
J Intern Med (ISSN: 0954-6820), 2017 May 26; N/D: N/D-N/D.
Impact Factor: 6.754
Dettagli Esporta in BibTeX Esporta in EndNote
Brunò E, Buemi MR, Di Fiore A, De LucaL, Ferro S, Angeli A, Cirilli R, Sadutto D, Alterio V, Monti SM, Supuran CT, De Simone G, Gitto R
* Probing Molecular Interactions between Human Carbonic Anhydrases (hCAs) and a Novel Class of Benzenesulfonamides (351 visite)
J Med Chem (ISSN: 0022-2623, 1520-4804, 0022-2623print), 2017 May 25; 60(10): 4316-4326.
Impact Factor: 6.253
Dettagli Esporta in BibTeX Esporta in EndNote
Buonanno M, Langella E, Zambrano N, Succoio M, Sasso E, Alterio V, Di Fiore A, Sandomenico A, Supuran CT, Scaloni A, Monti SM, De Simone G
* Disclosing the Interaction of Carbonic Anhydrase IX with Cullin-Associated NEDD8-Dissociated Protein 1 by Molecular Modeling and Integrated Binding Measurements (245 visite)
Acs Chem Biol (ISSN: 1554-8929), 2017 Apr 19; N/D: N/D-N/D.
Impact Factor: 4.592
Dettagli Esporta in BibTeX Esporta in EndNote
Mishra CB, Kumari S, Angeli A, Monti SM, Buonanno M, Tiwari M, Supuran CT
* Discovery of Benzenesulfonamides with Potent Human Carbonic Anhydrase Inhibitory and Effective Anticonvulsant Action: Design, Synthesis, and Pharmacological Assessment (306 visite)
J Med Chem (ISSN: 0022-2623, 1520-4804, 0022-2623print), 2017 Mar 23; 60(6): 2456-2469.
Impact Factor: 6.253
Dettagli Esporta in BibTeX Esporta in EndNote
Altug C, Gunes H, Nocentini A, Monti SM, Buonanno M, Supuran CT
* Synthesis of isoxazole-containing sulfonamides with potent carbonic anhydrase II and VII inhibitory properties (254 visite)
Bioorg Med Chem (ISSN: 0968-0896, 1464-3391), 2017 Feb 15; 25(4): 1456-1464.
Impact Factor: 2.881
Dettagli Esporta in BibTeX Esporta in EndNote
Angapelly S, Ramya PV, Angeli A, Monti SM, Buonanno M, Alvala M, Supuran CT, Arifuddin M
* Discovery of 4-sulfamoyl-phenyl-beta-lactams as a new class of potent carbonic anhydrase isoforms I, II, IV and VII inhibitors: The first example of subnanomolar CA IV inhibitors (274 visite)
Bioorg Med Chem (ISSN: 0968-0896, 1464-3391), 2017 Jan 15; pii:S0968-0896(16): 539-544.
Impact Factor: 2.881
Dettagli Esporta in BibTeX Esporta in EndNote
Angapelly S, Ramya PVS, Angeli A, Monti SM, Buonanno M, Alvala M, Supuran CT, Arifuddin M
* Discovery of 4-sulfamoyl-phenyl-β-lactams as a new class of potent carbonic anhydrase isoforms I, II, IV and VII inhibitors: The first example of subnanomolar CA IV inhibitors (218 visite)
Bioorg Med Chem (ISSN: 0968-0896, 1464-3391), 2017; 25(2): 539-544.
Impact Factor: 2.881
Dettagli Esporta in BibTeX Esporta in EndNote
Bozzetto L, Costabile G, Luongo D, Naviglio D, Cicala V, Piantadosi C, Patti L, Cipriano P, Annuzzi G, Rivellese AA
* Reduction in liver fat by dietary MUFA in type 2 diabetes is helped by enhanced hepatic fat oxidation (185 visite)
Diabetologia (ISSN: 0012-186x), 2016 Dec; 59(12): 2697-2701.
Impact Factor: 6.08
Dettagli Esporta in BibTeX Esporta in EndNote
Alterio V, Cadoni R, Esposito D, Vullo D, Fiore AD, Monti SM, Caporale A, Ruvo M, Sechi M, Dumy P, Supuran CT, De Simone G, Winum JY
* Benzoxaborole as a new chemotype for carbonic anhydrase inhibition (326 visite)
Chem Commun (ISSN: 1359-7345, 1364-548x, 1364-548xelectronic), 2016 Sep 29; 52(80): 11983-11986.
Impact Factor: 6.319
Dettagli Esporta in BibTeX Esporta in EndNote
Vullo D, Supuran CT, Scozzafava A, De Simone G, Monti SM, Alterio V, Carta F
* Kinetic and X-ray crystallographic investigations of substituted 2-thio-6-oxo-1, 6-dihydropyrimidine-benzenesulfonamides acting as carbonic anhydrase inhibitors (222 visite)
Bioorg Med Chem (ISSN: 0968-0896, 1464-3391), 2016 Aug 15; 24(16): 3643-3648.
Impact Factor: 2.93
Dettagli Esporta in BibTeX Esporta in EndNote
Di Fiore A, De Simone G, Alterio V, Riccio V, Winum JY, Carta F, Supuran CT
* The anticonvulsant sulfamide JNJ-26990990 and its S, S-dioxide analog strongly inhibit carbonic anhydrases: solution and X-ray crystallographic studies (213 visite)
Org Biomol Chem (ISSN: 1477-0520, 1477-0539, 1477-0539electronic), 2016 Jun 07; 14(21): 4853-4858.
Impact Factor: 3.564
Dettagli Esporta in BibTeX Esporta in EndNote
Del Prete S, De Luca V, De Simone G, Supuran CT, Capasso C
* Cloning, expression and purification of the complete domain of the eta-carbonic anhydrase from Plasmodium falciparum (325 visite)
J Enzym Inhib Med Ch (ISSN: 1475-6366, 1475-6374electronic, 1475-6366linking), 2016 Jun; 31(sup4): 54-59.
Impact Factor: 4.293
Dettagli Esporta in BibTeX Esporta in EndNote
Langella E, D'Ambrosio K, D'Ascenzio M, Carradori S, Monti SM, Supuran CT, De Simone G
* A Combined Crystallographic and Theoretical Study Explains the Capability of Carboxylic Acids to Adopt Multiple Binding Modes in the Active Site of Carbonic Anhydrases (285 visite)
Chemistry (ISSN: 0947-6539, 1521-3765, 1521-3765electronic), 2016 Jan 4; 22(1): 97-100.
Impact Factor: 5.317
Dettagli Esporta in BibTeX Esporta in EndNote
Mishra CB, Kumari S, Angeli A, Monti SM, Buonanno M, Prakash A, Tiwari M, Supuran CT
* Design, synthesis and biological evaluation of N-(5-methyl-isoxazol-3-yl/1, 3, 4-thiadiazol-2-yl)-4-(3-substitutedphenylureido) benzenesulfonamides as human carbonic anhydrase isoenzymes I, II, VII and XII inhibitors (257 visite)
J Enzyme Inhib Med Chem, 2016; 17: 1-6.
Impact Factor: 3.428
Dettagli Esporta in BibTeX Esporta in EndNote
Mollica A, Locatelli M, Macedonio G, Carradori S, Sobolev AP, De Salvador RF, Monti SM, Buonanno M, Zengin G, Angeli A, Supuran CT
* Microwave-assisted extraction, HPLC analysis, and inhibitory effects on carbonic anhydrase I, II, VA, and VII isoforms of 14 blueberry Italian cultivars (212 visite)
J Enzyme Inhib Med Chem, 2016; 31(sup4): N/D-N/D.
Impact Factor: 3.428
Dettagli Esporta in BibTeX Esporta in EndNote
La Regina G, Coluccia A, Famiglini V, Pelliccia S, Monti L, Vullo D, Nuti E, Alterio V, De Simone G, Monti SM, Pan P, Parkkila S, Supuran CT, Rossello A, Silvestri R
* Discovery of 1, 1'-Biphenyl-4-sulfonamides as a New Class of Potent and Selective Carbonic Anhydrase XIV Inhibitors (287 visite)
J Med Chem (ISSN: 0022-2623, 1520-4804, 0022-2623print), 2015 Nov 12; 58(21): 8564-8572.
Impact Factor: 5.589
Dettagli Esporta in BibTeX Esporta in EndNote
Di Fiore A, Vergara A, Caterino M, Alterio V, Monti SM, Ombouma J, Dumy P, Vullo D, Supuran CT, Winum JY, De Simone G
* Hydroxylamine-O-sulfonamide is a versatile lead compound for the development of carbonic anhydrase inhibitors (284 visite) (PDF 208 visite)
Chem Commun (ISSN: 1359-7345, 1364-548x, 1364-548xelectronic), 2015 Jul 2; 51(57): 11519-11522.
Impact Factor: 6.567
Dettagli Esporta in BibTeX Esporta in EndNote
De Simone G, Monti SM, Alterio V, Buonanno M, De Luca V, Rossi M, Carginale V, Supuran CT, Capasso C, Di Fiore A
* Crystal structure of the most catalytically effective carbonic anhydrase enzyme known, SazCA from the thermophilic bacterium Sulfurihydrogenibium azorense (249 visite)
Bioorg Med Chem Lett (ISSN: 0960-894x), 2015 May 1; 25(9): 2002-2006.
Impact Factor: 2.486
Dettagli Esporta in BibTeX Esporta in EndNote
Alterio V, Tanc M, Ivanova J, Zalubovskis R, Vozny I, Monti SM, Di Fiore A, De Simone G, Supuran CT
* X-ray crystallographic and kinetic investigations of 6-sulfamoyl-saccharin as a carbonic anhydrase inhibitor (306 visite)
Org Biomol Chem (ISSN: 1477-0520, 1477-0539, 1477-0539electronic), 2015 Apr 7; 13(13): 4064-4069.
Impact Factor: 3.559
Dettagli Esporta in BibTeX Esporta in EndNote
De Simone G, Di Fiore A, Capasso C, Supuran CT
* The zinc coordination pattern in the eta-carbonic anhydrase from Plasmodium falciparum is different from all other carbonic anhydrase genetic families (433 visite)
Bioorg Med Chem Lett (ISSN: 0960-894x), 2015 Apr 1; 25(7): 1385-1389.
Impact Factor: 2.486
Dettagli Esporta in BibTeX Esporta in EndNote
Alterio V, Langella E, De Simone G, Monti SM
* Cadmium-containing carbonic anhydrase CDCA1 in marine diatom Thalassiosira weissflogii (428 visite)
Mar Drugs (ISSN: 1660-3397, 1660-3397linking), 2015 Mar 25; 13(4): 1688-1697.
Impact Factor: 3.345
Dettagli Esporta in BibTeX Esporta in EndNote
Monti SM, Supuran CT, De Simone G
* DPP-4 inhibitors: a patent review (2012 - 2014) (337 visite)
Expert Opin Ther Pat (ISSN: 1354-3776, 1744-7674electronic), 2015 Feb; 25(2): 209-236.
Impact Factor: 4.626
Dettagli Esporta in BibTeX Esporta in EndNote
Supuran CT, Capasso C, De Simone G
* Carbonic Anhydrase II as Target for Drug Design (235 visite)
Carbonic Anhydrases As Biocatalysts, 2015 Jan 08; N/D: 51-90.
Impact Factor: 0
Dettagli Esporta in BibTeX Esporta in EndNote
Monti SM, Supuran CT, De Simone G, Di Fiore A
* Carbonic Anhydrase VII (187 visite)
Carbonic Anhydrases As Biocatalysts, 2015 Jan 08; N/D: 151-168.
Impact Factor: 0
Dettagli Esporta in BibTeX Esporta in EndNote
Supuran CT, De Simone G
Carbonic Anhydrases: An Overview (207 visite)
Carbonic Anhydrases As Biocatalysts, 2015 Jan 08; N/D: 3-13.
Impact Factor: 0
Dettagli Esporta in BibTeX Esporta in EndNote
D'Ambrosio K, De Simone G, Supuran CT
* Human Carbonic Anhydrases: Catalytic Properties, Structural Features, and Tissue Distribution (251 visite)
Carbonic Anhydrases As Biocatalysts, 2015 Jan 08; N/D: 17-30.
Impact Factor: 0
Dettagli Esporta in BibTeX Esporta in EndNote
D'Ambrosio K, Carradori S, Monti SM, Buonanno M, Secci D, Vullo D, Supuran CT, De Simone G
* Out of the active site binding pocket for carbonic anhydrase inhibitors (341 visite) (PDF 228 visite)
Chem Commun (ISSN: 1359-7345, 1364-548x, 1364-548xelectronic), 2015 Jan 7; 51(2): 302-305.
Impact Factor: 6.567
Dettagli Esporta in BibTeX Esporta in EndNote
Ceruso M, Carta F, Osman SM, Alothman Z, Monti SM, Supuran CT
* Inhibition studies of bacterial, fungal and protozoan β-class carbonic anhydrases with Schiff bases incorporating sulfonamide moieties (326 visite)
Bioorg Med Chem (ISSN: 0968-0896, 1464-3391), 2015; 23(15): 4181-4187.
Impact Factor: 2.923
Dettagli Esporta in BibTeX Esporta in EndNote
Iqbal J, Al-rashida M, Durdagi S, Alterio V, Di Fiore A
* Recent developments of carbonic anhydrase inhibitors as potential drugs (377 visite)
Biomed Res Int (ISSN: 2314-6133, 2314-6141), 2015; 2015: 174178-174178.
Impact Factor: 2.134
Dettagli Esporta in BibTeX Esporta in EndNote
Di Fiore A, Alterio V, Monti SM, De Simone G, D’Ambrosio K
* Thermostable carbonic anhydrases in biotechnological applications (407 visite)
Int J Mol Sc (ISSN: 1422-0067, 1661-6596, 1422-0067linking), 2015; 16(7): 15456-15480.
Impact Factor: 3.257
Dettagli Esporta in BibTeX Esporta in EndNote
De Simone R, Ranieri A, Montella S, Cappabianca P, Quarantelli M, Esposito F, Cardillo G, Bonavita V
* Intracranial pressure in unresponsive chronic migraine (369 visite)
J Neurol (ISSN: 0340-5354, 1432-1459, 0340-5354print), 2014 Jul; 261(7): 1365-1373.
Impact Factor: 3.377
Dettagli Esporta in BibTeX Esporta in EndNote
Bilo L, Peluso S, Antenora A, De Rosa A, Auletta G, Pappata S, De Michele G
* Parkinsonism may be part of the symptom complex of DOOR syndrome (220 visite)
Parkinsonism Relat D (ISSN: 1353-8020, 1873-5126, 1353-8020print), 2014 Apr; 20(4): 463-465.
Impact Factor: 3.972
Dettagli Esporta in BibTeX Esporta in EndNote
Dathan NA, Alterio V, Troiano E, Vullo D, Ludwig M, De Simone G, Supuran CT, Monti SM
* Biochemical Characterization Of The Chloroplastic β-Carbonic Anhydrase From Flaveria Bidentis (l. ) "kuntze" (346 visite)
J Enzym Inhib Med Ch (ISSN: 1475-6366, 1475-6374electronic, 1475-6366linking), 2014; 29(4): 500-504.
Impact Factor: 2.332
Dettagli Esporta in BibTeX Esporta in EndNote
De Simone G, Pizika G, Monti SM, Di Fiore A, Ivanova J, Vozny I, Trapencieris P, Zalubovskis R, Supuran CT, Alterio V
* Hydrophobic substituents of the phenylmethylsulfamide moiety can be used for the development of new selective carbonic anhydrase inhibitors (309 visite)
Biomed Res Int (ISSN: 2314-6133, 2314-6141), 2014; 2014: 523210-523210.
Impact Factor: 1.579
Dettagli Esporta in BibTeX Esporta in EndNote
Alterio V, Pan P, Parkkila S, Buonanno M, Supuran CT, Monti SM, De Simone G
* The Structural Comparison Between Membrane-Associated Human Carbonic Anhydrases Provides Insights Into Drug Design Of Selective Inhibitors (370 visite)
Biopolymers (ISSN: 0006-3525, 0006-6352, 0006-3525print), 2014; 101(7): 769-778.
Impact Factor: 2.385
Dettagli Esporta in BibTeX Esporta in EndNote
Alterio V, Monti SM, De Simone G
* Thermal-stable carbonic anhydrases: a structural overview (346 visite)
Subcell Biochem (ISSN: 0306-0225), 2014; 75: 387-404.
Impact Factor: 33.116
Dettagli Esporta in BibTeX Esporta in EndNote
Pedone C, Napoli N, Pozzilli P, Lauretani F, Bandinelli S, Ferrucci L, Rossi FF, Antonelli Incalzi R
* Bone health as a function of adipokines and vitamin D pattern in elderly patients (258 visite)
Rejuv Res (ISSN: 1557-8577, 1549-1684), 2013 Dec; 16(6): 467-474.
Impact Factor: 3.931
Dettagli Esporta in BibTeX Esporta in EndNote
Rami M, Dubois L, Parvathaneni NK, Alterio V, van Kuijk SJ, Monti SM, Lambin P, De Simone G, Supuran CT, Winum JY
* Hypoxia-targeting carbonic anhydrase IX inhibitors by a new series of nitroimidazole-sulfonamides/sulfamides/sulfamates (471 visite)
J Med Chem (ISSN: 0022-2623, 1520-4804, 0022-2623print), 2013 Nov 14; 56(21): 8512-8520.
Impact Factor: 5.48
Dettagli Esporta in BibTeX Esporta in EndNote
De Simone G, Alterio V, Supuran CT
* Exploiting the hydrophobic and hydrophilic binding sites for designing carbonic anhydrase inhibitors (376 visite)
Expert Opin Drug Discov (ISSN: 1746-0441), 2013 Jul; 8(7): 793-810.
Impact Factor: 3.467
Dettagli Esporta in BibTeX Esporta in EndNote
Monti SM, Supuran CT, De Simone G
* Anticancer carbonic anhydrase inhibitors: A patent review (2008-2013) (379 visite)
Expert Opin Ther Pat (ISSN: 1354-3776, 1744-7674electronic), 2013 Jun; 23(6): 737-749.
Impact Factor: 3.441
Dettagli Esporta in BibTeX Esporta in EndNote
Di Fiore A, Capasso C, De Luca V, Monti SM, Carginale V, Supuran CT, Scozzafava A, Pedone C, Rossi M, De Simone G
* X-ray structure of the first 'extremo-alpha-carbonic anhydrase', a dimeric enzyme from the thermophilic bacterium Sulfurihydrogenibium yellowstonense YO3AOP1 (377 visite)
Acta Crystallogr D Biol Crystallogr (ISSN: 0907-4449, 0907-4449linking), 2013 Jun; 69(6): 1150-1159.
Impact Factor: 7.232
Dettagli Esporta in BibTeX Esporta in EndNote
Monti SM, De Simone G, Dathan NA, Ludwig M, Vullo D, Scozzafava A, Capasso C, Supuran CT
* Kinetic And Anion Inhibition Studies Of A Beta-Carbonic Anhydrase (fbica 1) From The C-4 Plant Flaveria Bidentis (384 visite)
Bioorg Med Chem Lett (ISSN: 0960-894x), 2013 Mar 15; 23(6): 1626-1630.
Impact Factor: 2.331
Dettagli Esporta in BibTeX Esporta in EndNote
Buanne P, Renzone G, Monteleone F, Vitale M, Monti SM, Sandomenico A, Garbi C, Montanaro D, Accardo M, Troncone G, Zatovicova M, Csaderova L, Supuran CT, Pastorekova S, Scaloni A, De Simone G, Zambrano N
* Characterization of carbonic anhydrase ix interactome reveals proteins assisting its nuclear localization in hypoxic cells (338 visite)
J Proteome Res (ISSN: 1535-3893), 2013 Jan; 12(1): 282-292.
Impact Factor: 5.001
Dettagli Esporta in BibTeX Esporta in EndNote
Del Giudice R, Monti DM, Truppo E, Arciello A, Supuran CT, De Simone G, Monti SM
* Human Carbonic Anhydrase Vii Protects Cells From Oxidative Damage (320 visite)
Biol Chem Biological Chemistry (ISSN: 1431-6730, 1431-1673, 1437-4315), 2013; 394(10): 1343-1348.
Impact Factor: 2.689
Dettagli Esporta in BibTeX Esporta in EndNote
Alterio V, Di Fiore A, D'Ambrosio K, Supuran CT, De Simone G
* Multiple binding modes of inhibitors to carbonic anhydrases: How to design specific drugs targeting 15 different isoforms? (385 visite)
Chem Rev (ISSN: 0009-2665), 2012 Sep; 112(8): 4421-4468.
Impact Factor: 41.298
Dettagli Esporta in BibTeX Esporta in EndNote
De Simone G, Supuran CT
* (In)organic anions as carbonic anhydrase inhibitors (342 visite)
J Chem Res (ISSN: 0162-0134, 1873-3344, 0162-0134print), 2012 Jun; 111: 117-129.
Impact Factor: 3.197
Dettagli Esporta in BibTeX Esporta in EndNote
Alterio V, Langella E, Viparelli F, Vullo D, Ascione G, Dathan NA, Morel FM, Supuran CT, De Simone G, Monti SM
* Structural and inhibition insights into carbonic anhydrase CDCA1 from the marine diatom Thalassiosira weissflogii (371 visite)
Biochimie (ISSN: 0300-9084, 1638-6183, 1638-6183electronic), 2012 May; 94(5): 1232-1241.
Impact Factor: 3.142
Dettagli Esporta in BibTeX Esporta in EndNote
Truppo E, Supuran CT, Sandomenico A, Vullo D, Innocenti A, Di Fiore A, Alterio V, De Simone G, Monti SM
* Carbonic anhydrase VII is S-glutathionylated without loss of catalytic activity and affinity for sulfonamide inhibitors (333 visite)
Bioorg Med Chem Lett Bioorganic And Medicinal Chemistry Letters (ISSN: 0960-894x), 2012 Feb 15; 22(4): 1560-1564.
Impact Factor: 2.338
Dettagli Esporta in BibTeX Esporta in EndNote
Monti SM, Supuran CT, De Simone G
* Carbonic anhydrase IX as a target for designing novel anticancer drugs (415 visite)
Curr Med Chem (ISSN: 0929-8673, 1875-533x, 1875-533xelectronic), 2012 Feb; 19(6): 821-830.
Impact Factor: 4.07
Dettagli Esporta in BibTeX Esporta in EndNote
De Simone G
* Editorial: Zinc Metallo-Enzymes As Target For Drug Design (338 visite)
Curr Med Chem (ISSN: 0929-8673, 1875-533x, 1875-533xelectronic), 2012 Feb; 19(6): 820-1012.
Impact Factor: 4.07
Dettagli Esporta in BibTeX Esporta in EndNote
Monti SM, Maresca A, Viparelli F, Carta F, De Simone G, Muehlschlegel FA, Scozzafava A, Supuran CT
* Dithiocarbamates are strong inhibitors of the beta-class fungal carbonic anhydrases from Cryptococcus neoformans, Candida albicans and Candida glabrata (330 visite)
Bioorg Med Chem Lett (ISSN: 0960-894x), 2012 Jan 15; 22(2): 859-862.
Impact Factor: 2.338
Dettagli Esporta in BibTeX Esporta in EndNote
D'Ambrosio K, Smaine F-Z, Carta F, De Simone G, Winum J-Y, Supuran CT
* Development of potent carbonic anhydrase inhibitors incorporating both sulfonamide and sulfamide groups (406 visite)
J Med Chem (ISSN: 0022-2623, 1520-4804, 0022-2623print), 2012; 55(15): 6776-6783.
Impact Factor: 5.614
Dettagli Esporta in BibTeX Esporta in EndNote
Di Fiore A, Maresca A, Supuran CT, De Simone G
* Hydroxamate represents a versatile zinc binding group for the development of new carbonic anhydrase inhibitors (316 visite)
Chem Commun (ISSN: 1359-7345, 1364-548x, 1364-548xelectronic), 2012; 48(70): 8838-8840.
Impact Factor: 6.378
Dettagli Esporta in BibTeX Esporta in EndNote
Di Fiore A, Maresca A, Alterio V, Supuran CT, De Simone G
* Carbonic anhydrase inhibitors: X-ray crystallographic studies for the binding of N-substituted benzenesulfonamides to human isoform II (314 visite)
Chem Commun (ISSN: 1359-7345, 1364-548x, 1364-548xelectronic), 2011; 47(42): 11636-11638.
Impact Factor: 6.169
Dettagli Esporta in BibTeX Esporta in EndNote
Viparelli F, Monti SM, De Simone G, Innocenti A, Scozzafava A, Xu Y, Morel FMM, Supuran CT
* Inhibition Of The R1 Fragment Of The Cadmium-Containing Zeta-Class Carbonic Anhydrase From The Diatom Thalassiosira Weissflogii With Anions (296 visite)
Bioorganic & Medicinal Chemistry Letters (ISSN: 0960-894x), 2010 Sep 15; 20(16): 4745-4748.
Impact Factor: 2.661
Dettagli Esporta in BibTeX Esporta in EndNote
Alterio V, Monti SM, Truppo E, Pedone C, Supuran CT, De Simone G
* The first example of a significant active site conformational rearrangement in a carbonic anhydrase-inhibitor adduct: The carbonic anhydrase I-topiramate complex (359 visite)
Org Biomol Chem (ISSN: 1477-0520, 1477-0539, 1477-0539electronic), 2010 Sep 7; 8(15): 3528-3533.
Impact Factor: 3.451
Dettagli Esporta in BibTeX Esporta in EndNote
Di Fiore A, Truppo E, Supuran CT, Alterio V, Dathan N, Bootorabi F, Parkkila S, Monti SM, De Simone G
* Crystal structure of the C183S/C217S mutant of human CA VII in complex with acetazolamide (276 visite)
Bioorg Med Chem Lett (ISSN: 0960-894x), 2010 Sep 1; 20(17): 5023-5026.
Impact Factor: 2.661
Dettagli Esporta in BibTeX Esporta in EndNote
Di Fiore A, Monti SM, Innocenti A, Winum J-Y, De Simone G, Supuran CT
* Carbonic anhydrase inhibitors: Crystallographic and solution binding studies for the interaction of a boron-containing aromatic sulfamide with mammalian isoforms I-XV (304 visite)
Bioorg Med Chem Lett Bioorganic And Medicinal Chemistry Letters (ISSN: 0960-894x), 2010 Jun 15; 20(12): 3601-3605.
Impact Factor: 2.661
Dettagli Esporta in BibTeX Esporta in EndNote
De Simone G, Supuran CT
* Carbonic anhydrase IX: Biochemical and crystallographic characterization of a novel antitumor target (354 visite)
Bba-Gen Subjects (ISSN: 1570-9639, 0006-3002, 0925-4439), 2010 Feb; 1804(2): 404-409.
Impact Factor: 2.773
Dettagli Esporta in BibTeX Esporta in EndNote
Guler OO, De Simone G, Supuran CT
* Drug design studies of the novel antitumor targets carbonic anhydrase IX and XII (430 visite)
Curr Med Chem (ISSN: 0929-8673, 1875-533x, 1875-533xelectronic), 2010; 17(15): 1516-1526.
Impact Factor: 4.63
Dettagli Esporta in BibTeX Esporta in EndNote
Supuran CT, Di Fiore A, Alterio V, Monti SM, De Simone G
* Recent advances in structural studies of the carbonic anhydrase family: The crystal structure of human CA IX and CA XIII (398 visite)
Curr Pharm Des Current Pharmaceutical Design (ISSN: 1381-6128, 1873-4286), 2010; 16(29): 3246-3254.
Impact Factor: 4.774
Dettagli Esporta in BibTeX Esporta in EndNote
Kapucu OL, Nobili F, Varrone A, Booij J, Vander Borght T, Nagren K, Darcourt J, Tatsch K, Van Laere KJ
* EANM procedure guideline for brain perfusion SPECT using Tc-99m-labelled radiopharmaceuticals, version (444 visite)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2009 Dec; 36(12): 2093-2102.
Impact Factor: 4.531
Dettagli Esporta in BibTeX Esporta in EndNote
Innocenti A, Pastorekova S, Pastorek J, Scozzafava A, De Simone G, Supuran CT
* The proteoglycan region of the tumor-associated carbonic anhydrase isoform IX acts as anintrinsic buffer optimizing CO2 hydration at acidic pH values characteristic of solid tumors (209 visite)
Bioorganic & Medicinal Chemistry Letters (ISSN: 0960-894x), 2009 Oct 15; 19(20): 5825-5828.
Impact Factor: 2.65
Dettagli Esporta in BibTeX Esporta in EndNote
Vitale RM, Alterio V, Innocenti A, Winum JY, Monti SM, De Simone G, Supuran CT
* Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis- sulfamate adducts with isozymes II and IX as a platform for designing tight-binding, more isoform-selective inhibitors (390 visite)
J Med Chem (ISSN: 0022-2623, 1520-4804, 0022-2623print), 2009 Oct 8; 52(19): 5990-5998.
Impact Factor: 4.802
Dettagli Esporta in BibTeX Esporta in EndNote
Alterio V, Hilvo M, Di Fiore A, Supuran CT, Pan P, Parkkila S, Scaloni A, Pastorek J, Pastorekova S, Pedone C, Scozzafava A, Monti SM, De Simone G
* Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX (472 visite)
P Natl Acad Sci Usa (ISSN: 0027-8424, 1091-6490, 0027-8424print), 2009 Sep 22; 106(38): 16233-16238.
Impact Factor: 9.432
Dettagli Esporta in BibTeX Esporta in EndNote
Coppola G, Fortunato D, Auricchio G, Mainolfi C, Operto FF, Signoriello G, Pascotto A, Salvatore M
* Bone mineral density in children, adolescents, and young adults with epilepsy (321 visite)
Epilepsia (ISSN: 1528-1167, 0013-9580), 2009 Sep; 50(9): 2140-2146.
Impact Factor: 4.052
Dettagli Esporta in BibTeX Esporta in EndNote
De Simone G, Scozzafava A, Supuran CT
* Which Carbonic Anhydrases are Targeted by the Antiepileptic Sulfonamides and Sulfamates? (301 visite)
Chem Biol Drug Des Chemical Biology And Drug Design (ISSN: 1747-0277, 1747-0285), 2009 Sep; 74(3): 317-321.
Impact Factor: 2.473
Dettagli Esporta in BibTeX Esporta in EndNote
Di Fiore A, Monti SM, Hilvo M, Parkkila S, Romano V, Scaloni A, Pedone C, Scozzafava A, Supuran CT, De Simone G
* Crystal structure of human carbonic anhydrase XIII and its complex with the inhibitor acetazolamide (406 visite)
Proteins (ISSN: 1097-0134, 0887-3585, 1097-0134electronic), 2009 Jan; 74(1): 164-175.
Impact Factor: 3.085
Dettagli Esporta in BibTeX Esporta in EndNote
Hilvo M, De Simone G, Supuran CT, Parkkila S
* Advances in the Inhibitory and Structural Investigations on Carbonic Anhydrase Isozymes XIII and XV (246 visite)
Drug Des Of Zinc Enzyme Inhibitors (ISSN: 9780-4702, 9780-470275009), 2009; N/D: 273-283.
Impact Factor: 1.156
Dettagli Esporta in BibTeX Esporta in EndNote
De Simone G, Supuran CT
* Drug Design of Antiobesity Carbonic Anhydrase Inhibitors (289 visite)
Drug Des Of Zinc Enzyme Inhibitors (ISSN: 9780-4702, 9780-470275009), 2009; 66(DECEMBERSPEC.I): 241-254.
Impact Factor: 1.156
Dettagli Esporta in BibTeX Esporta in EndNote
Alterio V, Di Fiore A, D'Ambrosio K, Supuran CT, De Simone G
* X-Ray Crystallography of Carbonic Anhydrase Inhibitors and Its Importance in Drug Design (315 visite)
Drug Des Of Zinc Enzyme Inhibitors (ISSN: 9780-4702, 9780-470275009), 2009; N/D: 73-138.
Impact Factor: 1.156
Dettagli Esporta in BibTeX Esporta in EndNote
Hilvo M, Baranauskiene L, Salzano AM, Scaloni A, Matulis D, Innocenti A, Scozzafava A, Monti SM, Di Fiore A, De Simone G, Lindfors M, Janis J, Valjakka J, Pastorekova S, Pastorek J, Kulomaa MS, Nordlund HR, Supuran CT, Parkkila S
* Biochemical characterization of CA IX, one of the most active carbonic anhydrase isozymes (381 visite)
Jbc Papers (ISSN: 0021-9258, 1083-351x, 0021-9258linking), 2008 Oct 10; 283(41): 27799-27809.
Impact Factor: 5.52
Dettagli Esporta in BibTeX Esporta in EndNote
D'Ambrosio K, Vitale R, Dogne J, Masereel B, Innocenti A, Scozzafava A, De Simone G, Supuran CT
* Ccarbonic Anhydrase Inhibitors: Bioreductive Nitro-Containing Sulfonamides With Selectivity For Targeting The Tumor Associated Isoforms Ix And Xii (435 visite)
J Med Chem (ISSN: 1520-4804, 0022-2623, 0022-2623print), 2008 Jun 12; 51(11): 3230-3237.
Impact Factor: 4.898
Dettagli Esporta in BibTeX Esporta in EndNote
Di Fiore A, Pedone C, Antel J, Waldeck H, Witte A, Wurl M, Scozzafava A, Supuran CT, De Simone G
* Carbonic anhydrase inhibitors: the X-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors (358 visite)
Bioorg Med Chem Lett (ISSN: 1464-3405, 0960-894x, 1464-3405electronic), 2008 Apr 15; 18(8): 2669-2674.
Impact Factor: 2.531
Dettagli Esporta in BibTeX Esporta in EndNote
Innocenti A, Scozzafava A, Parkkila S, Puccetti L, De Simone G, Supuran CT
* Investigations of the esterase, phosphatase, and sulfatase activities of the cytosolic mammalian carbonic anhydrase isoforms I, II, and XIII with 4-nitrophenyl esters as substrates (336 visite)
Bioorg Med Chem Lett Bioorganic And Medicinal Chemistry Letters (ISSN: 0960-894x), 2008 Apr 1; 18(7): 2267-2271.
Impact Factor: 2.531
Dettagli Esporta in BibTeX Esporta in EndNote
Leese MP, Jourdan FL, Gaukroger K, Mahon MF, Newman SP, Foster PA, Stengel C, Regis-Lydi S, Ferrandis E, Di Fiore A, De Simone G, Supuran CT, Purohit A, Reed MJ, Potter BVL
* Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents (380 visite)
J Med Chem (ISSN: 0022-2623, 1520-4804, 0022-2623print), 2008 Mar 13; 51(5): 1295-1308.
Impact Factor: 4.898
Dettagli Esporta in BibTeX Esporta in EndNote
De Simone G, Di Fiore A, Supuran CT
* Are carbonic anhydrase inhibitors suitable for obtaining antiobesity drugs? (356 visite)
Curr Pharm Des Current Pharmaceutical Design (ISSN: 1381-6128, 1873-4286), 2008 Mar; 14(7): 655-660.
Impact Factor: 4.399
Dettagli Esporta in BibTeX Esporta in EndNote
D'Ambrosio K, Masereel B, Thiry A, Scozzafava A, Supuran CT, De Simone G
* Carbonic anhydrase inhibitors: Binding of indanesulfonamides to the human isoform II (330 visite)
Chemmedchem (ISSN: 1860-7179, 1860-7187, 1860-7187electronic), 2008 Mar; 3(3): 473-477.
Impact Factor: 3.15
Dettagli Esporta in BibTeX Esporta in EndNote
Supuran CT, De Simone G
Carbonic anhydrases--an overview (315 visite)
Curr Pharm Des, 2008; 14(7): 603-614.
Impact Factor: 0
Dettagli Esporta in BibTeX Esporta in EndNote
Hilvo M, Innocenti A, Monti SM, De Simone G, Supuran CT, Parkkila S
* Recent advances in research on the most novel carbonic anhydrases, CA XIII and XV (326 visite)
Curr Pharm Des Current Pharmaceutical Design (ISSN: 1381-6128, 1873-4286), 2008; 14(7): 672-678.
Impact Factor: 4.399
Dettagli Esporta in BibTeX Esporta in EndNote
Alterio V, De Simone G, Monti SM, Scozzafava A, Supuran CT
* Carbonic anhydrase inhibitors: Inhibition of human, bacterial, and archaeal isozymes with benzene-1, 3-disulfonamides-Solution and crystallographic studies (301 visite)
Bioorg Med Chem Lett Bioorganic And Medicinal Chemistry Letters (ISSN: 0960-894x), 2007 Sep 1; 17(15): 4201-4207.
Impact Factor: 2.604
Dettagli Esporta in BibTeX Esporta in EndNote
Vitale RM, Pedone C, Amodeo P, Antel J, Wurl M, Scozzafava A, Supuran CT, De Simone G
* Molecular modeling study for the binding of zonisamide and topiramate to the human mitochondrial carbonic anhydrase isoform VA (308 visite)
Bioorg Med Chem (ISSN: 0968-0896, 1464-3391, 1464-3391electronic), 2007 Jun 15; 15(12): 4152-4158.
Impact Factor: 2.662
Dettagli Esporta in BibTeX Esporta in EndNote
Di Fiore A, Scozzafava A, Winum JY, Montero JL, Pedone C, Supuran CT, De Simone G
* Carbonic anhydrase inhibitors: binding of an antiglaucoma glycosyl-sulfanilamide derivative to human isoform II and its consequences for the drug design of enzyme inhibitors incorporating sugar moieties (384 visite)
Bioorg Med Chem Lett Bioorganic And Medicinal Chemistry Letters (ISSN: 0960-894x), 2007 Mar 15; 17(6): 1726-1731.
Impact Factor: 2.604
Dettagli Esporta in BibTeX Esporta in EndNote
De Simone G, Supuran CT
* Antiobesity carbonic anhydrase inhibitors (393 visite)
Curr Top Med Chem (ISSN: 1568-0266, 1568-0266linking, 1873-4294electronic), 2007; 7(9): 879-884.
Impact Factor: 4.325
Dettagli Esporta in BibTeX Esporta in EndNote
Leese MP, Leblond B, Smith A, Newman SP, Di Fiore A, De Simone G, Supuran CT, Purohit A, Reed MJ, Potter BVL
* 2-substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity (795 visite)
J Med Chem (ISSN: 0022-2623print, 0022-2623linking, 1520-4804), 2006 Dec 28; 49(26): 7683-7696.
Impact Factor: 5.115
Dettagli Esporta in BibTeX Esporta in EndNote
Menchise V, De Simone G, Di Fiore A, Scozzafava A, Supuran CT
* Carbonic anhydrase inhibitors: X-ray crystallographic studies for the binding of 5-amino-1, 3, 4-thiadiazole-2-sulfonamide and 5-(4-amino-3-chloro-5-fluorophenylsulfonamido)1, 3, 4-thiadiazole-2-sulfon amide to human isoform II (277 visite)
Bioorganic & Medicinal Chemistry Letters (ISSN: 0960-894x), 2006 Dec 15; 16(24): 6204-6208.
Impact Factor: 2.538
Dettagli Esporta in BibTeX Esporta in EndNote
De Simone G, Vitale RM, Di Fiore A, Pedone C, Scozzafava A, Montero JL, Winum JY, Supuran CT
* Carbonic anhydrase inhibitors: Hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX (412 visite)
J Med Chem (ISSN: 0022-2623, 1520-4804, 0022-2623print), 2006 Sep 7; 49(18): 5544-5551.
Impact Factor: 5.115
Dettagli Esporta in BibTeX Esporta in EndNote
Alterio V, Vitale RM, Monti SM, Pedone C, Scozzafava A, Cecchi A, De Simone G, Supuran CT
* Carbonic anhydrase inhibitors: X-ray and molecular modeling study for the interaction of a fluorescent antitumor sulfonamide with isozyme II and IX (370 visite)
J Am Chem Soc (ISSN: 0002-7863, 0002-2786, 1520-5126), 2006 Jun 28; 128(25): 8329-8335.
Impact Factor: 7.696
Dettagli Esporta in BibTeX Esporta in EndNote
Di Fiore A, Pedone C, D'Ambrosio K, Scozzafava A, De Simone G, Supuran CT
* Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II 'selective' inhibitor celecoxib (289 visite)
Bioorg Med Chem Lett Bioorganic And Medicinal Chemistry Letters (ISSN: 0960-894x), 2006 Jan 15; 16(2): 437-442.
Impact Factor: 2.538
Dettagli Esporta in BibTeX Esporta in EndNote
Menchise V, De Simone G, Alterio V, Di Fiore A, Pedone C, Scozzafava A, Supuran CT
* Carbonic anhydrase inhibitors: Stacking with Phe131 determines active site binding region of inhibitors as exemplified by the X-ray crystal structure of a membrane-impermeant antitumor sulfonamide complexed with isozyme II (440 visite)
J Med Chem (ISSN: 0022-2623, 1520-4804, 0022-2623print), 2005 Sep 8; 48(18): 5721-5727.
Impact Factor: 4.926
Dettagli Esporta in BibTeX Esporta in EndNote
De Simone G, Di Fiore A, Menchise V, Pedone C, Antel J, Casini A, Scozzafava A, Wurl M, Supuran CT
* Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies (302 visite)
Bioorg Med Chem Lett Bioorganic And Medicinal Chemistry Letters (ISSN: 0960-894x), 2005 May 2; 15(9): 2315-2320.
Impact Factor: 2.478
Dettagli Esporta in BibTeX Esporta in EndNote
Di Fiore A, De Simone G, Menchise V, Pedone C, Casini A, Scozzafava A, Supuran CT
* Carbonic anhydrase inhibitors: X-ray crystal structure of a benzenesulfonamide strong CA II and CA IX inhibitor bearing a pentafluorophenylaminothioureido tail in complex with isozyme II (430 visite)
Bioorg Med Chem Lett Bioorganic And Medicinal Chemistry Letters (ISSN: 0960-894x), 2005 Apr 1; 15(7): 1937-1942.
Impact Factor: 2.478
Dettagli Esporta in BibTeX Esporta in EndNote
Fonti R, Latella G, Caprilli R, Frieri G, Marcheggiano A, Sambuy Y
Carbonic anhydrase I reduction in colonic mucosa of patients with active ulcerative colitis (237 visite)
Digestive Diseases And Sciences (ISSN: 0163-2116), 1998; 43(9): 2086-2092.
Impact Factor: 1.972
Dettagli Esporta in BibTeX Esporta in EndNote
Soricelli A, Postiglione A, Cuocolo A, De Chiara S, Ruocco A, Brunetti A, Salvatore M, Ell PJ
EFFECT OF ADENOSINE ON CEREBRAL BLOOD-FLOW AS EVALUATED BY SINGLE-PHOTON EMISSION COMPUTED-TOMOGRAPHY IN NORMAL SUBJECTS AND IN PATIENTS WITH OCCLUSIVE CAROTID DISEASE - A COMPARISON WITH ACETAZOLAMIDE (236 visite)
Stroke (ISSN: 0039-2499), 1995 Sep; 26(9): 1572-1576.
Impact Factor: 4.323
Dettagli Esporta in BibTeX Esporta in EndNote
Mancini M, De Chiara S, Ferrara LA, Gallotta G, Postiglione A
TRANSCRANIAL DOPPLER EVALUATION OF CEREBROVASCULAR REACTIVITY TO ACETAZOLAMIDE IN NORMAL SUBJECTS (564 visite)
15th World Congress Angiology Rome, 1989; 20(4): 284-284.
Impact Factor: 0
Dettagli Esporta in BibTeX Esporta in EndNote
Testino G, Leone S, Fagoonee S, Del Bas JM, Rodriguez B, Puiggros F, Marine S, Rodriguez MA, Morina D, Armengol L, Caimari A, Arola L, Cimini FA, Barchetta I, Carotti S, Bertoccini L, Baroni MG, Vespasiani-gentilucci U, Cavallo MG, Morini S, Nelson JE, Roth CL, Wilson LA, Yates KP, Aouizerat B, Morgan-stevenson V, Whalen E, Hoofnagle A, Mason M, Gersuk V, Yeh MM, Kowdley KV, Lee SM, Jun DW, Cho YK, Jang KS, Kucukazman M, Ata N, Dal K, Yeniova AO, Kefeli A, Basyigit S, Aktas B, Akin KO, Agladioglu K, Ure OS, Topal F, Nazligul Y, Beyan E, Ertugrul DT, Catena C, Cosma C, Camozzi V, Plebani M, Ermani M, Sechi LA, Fallo F, Goto Y, Ray MB, Mendenhall CL, French SW, Gartside PS
Serum vitamin A deficiency and increased intrahepatic expression of cytokeratin antigen in alcoholic liver disease (485 visite)
Hepatology (ISSN: 1827-1669electronic, 0026-4806linking), 1988 Sep; 83120693611123109(5): 1019-1026.
Impact Factor: 0.913
Dettagli Esporta in BibTeX Esporta in EndNote
Vai a fine pagina Versione per copia e incolla facile Esporta tutto in BibTeX Esporta tutto in EndNote
Urbański LJ, Angeli A, Hytönen VP, Di Fiore A, De Simone G, Parkkila S, Supuran CT
* Inhibition of the β-carbonic anhydrase from the protozoan pathogen Trichomonas vaginalis with sulphonamides (102 visite)
J Enzyme Inhib Med Chem (ISSN: 1475-6366linking), 2021 Dec; 36(1): 329-334.
Impact Factor: 4.673
Dettagli Esporta in BibTeX Esporta in EndNote
D’ambrosio K, Di Fiore A, Buonanno M, Kumari S, Tiwari M, Supuran CT, Mishra CB, Monti SM, De Simone G
* The crystal structures of 2-(4-benzhydrylpiperazin-1-yl)-N-(4-sulfamoylphenyl)acetamide in complex with human carbonic anhydrase II and VII provide insights into selective CA inhibitor development (53 visite)
New Journal Of Chemistry, 2021; 45: 147-152.
Impact Factor: 3.288
Dettagli Esporta in BibTeX Esporta in EndNote
Urbański LJ, Di Fiore A, Azizi L, Hytönen VP, Kuuslahti M, Buonanno M, Monti SM, Angeli A, Zolfaghari Emameh R, Supuran CT, De Simone G, Parkkila S
* Biochemical and structural characterisation of a protozoan beta-carbonic anhydrase from Trichomonas vaginalis (90 visite)
J Enzyme Inhib Med Chem (ISSN: 1475-6366linking), 2020 Dec; 35(1): 1292-1299.
Impact Factor: 4.673
Dettagli Esporta in BibTeX Esporta in EndNote
Di Fiore A, Supuran CT, Scaloni A, De Simone G
* Human carbonic anhydrases and post-translational modifications: a hidden world possibly affecting protein properties and functions (94 visite)
J Enzyme Inhib Med Chem (ISSN: 1475-6366linking), 2020 Dec; 35(1): 1450-1461.
Impact Factor: 4.673
Dettagli Esporta in BibTeX Esporta in EndNote
Urbański LJ, Angeli A, Hytönen VP, Di Fiore A, Parkkila S, De Simone G, Supuran CT
* Inhibition of the newly discovered β‑carbonic anhydrase from the protozoan pathogen Trichomonas vaginalis with inorganic anions and small molecules (54 visite)
J Inorg Biochem (ISSN: 0162-0134linking), 2020 Dec; 213: 111274-111274.
Impact Factor: 3.212
Dettagli Esporta in BibTeX Esporta in EndNote
Sarnella A, D'Avino G, Hill BS, Alterio V, Winum JY, Supuran CT, De Simone G, Zannetti A
* A Novel Inhibitor of Carbonic Anhydrases Prevents Hypoxia-Induced TNBC Cell Plasticity (41 visite) (PDF 12 visite)
Int J Mol Sci (ISSN: 1422-0067linking), 2020 Nov 9; 21(21): N/D-N/D.
Impact Factor: 4.556
Dettagli Esporta in BibTeX Esporta in EndNote
D'Ambrosio K, Carradori S, Cesa S, Angeli A, Monti SM, Supuran CT, De Simone G
* Catechols: a new class of carbonic anhydrase inhibitors (55 visite)
Chem Commun (ISSN: 1359-7345linking), 2020 Nov 4; 56(85): 13033-13033.
Impact Factor: 5.996
Dettagli Esporta in BibTeX Esporta in EndNote
Angeli A, Carta F, Nocentini A, Winum J, Zalubovskis R, Akdemir A, Onnis V, Eldehna WM, Capasso C, De Simone G, Monti Simona M, Carradori S, Donald WA, Dedhar S, Supuran CT
* Carbonic Anhydrase Inhibitors Targeting Metabolism and Tumor Microenvironment (56 visite)
Metabolites, 2020 Oct 14; 10: 412-412.
Impact Factor: 4.097
Dettagli Esporta in BibTeX Esporta in EndNote
Bozdag M, Supuran CT, Esposito D, Angeli A, Carta F, Monti SM, De Simone G, Alterio V
* 2-Mercaptobenzoxazoles: a class of carbonic anhydrase inhibitors with a novel binding mode to the enzyme active site (75 visite)
Chem Commun (ISSN: 1359-7345linking), 2020 Jul 23; 56(59): 8297-8300.
Impact Factor: 5.996
Dettagli Esporta in BibTeX Esporta in EndNote
Polito R, Costabile G, Nigro E, Giacco R, Vetrani C, Anniballi G, Luongo D, Riccardi G, Daniele A, Annuzzi G
* Nutritional factors influencing plasma adiponectin levels: results from a randomised controlled study with whole-grain cereals (142 visite) (PDF 70 visite)
Int J Food Sci Nutr (ISSN: 0963-7486linking), 2020 Jun; 71(4): 509-515.
Impact Factor: 1.451
Dettagli Esporta in BibTeX Esporta in EndNote
Nocentini A, Alterio V, Bua S, Micheli L, Esposito D, Buonanno M, Bartolucci G, Osman SM, Alothman ZA, Cirilli R, Pierini M, Monti SM, Di Cesare Mannelli L, Gratteri P, Ghelardini C, De Simone G, Supuran CT
* Phenyl(thio)phosphon(amid)ate Benzenesulfonamides as Potent and Selective Inhibitors of Human Carbonic Anhydrases II and VII Counteract Allodynia in a Mouse Model of Oxaliplatin-Induced Neuropathy (75 visite)
J Med Chem (ISSN: 0022-2623linking), 2020 May 28; 63(10): 5185-5200.
Impact Factor: 6.205
Dettagli Esporta in BibTeX Esporta in EndNote
Mancuso F, Di Fiore A, De Luca L, Angeli A, Monti SM, De Simone G, Supuran CT, Gitto R
* Looking toward the Rim of the Active Site Cavity of Druggable Human Carbonic Anhydrase Isoforms (73 visite)
Acs Med Chem Lett (ISSN: 1948-5875linking), 2020 May 14; 11(5): 1000-1005.
Impact Factor: 3.975
Dettagli Esporta in BibTeX Esporta in EndNote
Langella E, Buonanno M, De Simone G, Monti SM
* Intrinsically disordered features of carbonic anhydrase IX proteoglycan-like domain (57 visite)
Cell Mol Life Sci (ISSN: 1420-682xlinking), 2020; 21: 8405-8405.
Impact Factor: 6.496
Dettagli Esporta in BibTeX Esporta in EndNote
Alterio V, Kellner M, Esposito D, Liesche-starnecker F, Bua S, Supuran CT, Monti SM, Zeidler R, De Simone G
* Biochemical and structural insights into Carbonic Anhydrase XII/Fab6A10 complex (142 visite)
J Mol Biol (ISSN: 0022-2836linking, 1089-8638), 2019 Dec 6; 431(24): 4910-4921.
Impact Factor: 5.067
Dettagli Esporta in BibTeX Esporta in EndNote
De Simone G, Di Fiore A, Truppo E, Langella E, Vullo D, Supuran CT, Monti SM
* Exploration of the residues modulating the catalytic features of human carbonic anhydrase XIII by a site-specific mutagenesis approach (189 visite)
J Enzym Inhib Med Ch (ISSN: 1475-6366linking, 1475-6374electronic), 2019 Dec; 34(1): 1506-1510.
Impact Factor: 4.027
Dettagli Esporta in BibTeX Esporta in EndNote
Langella E, Alterio V, D'Ambrosio K, Cadoni R, Winum JY, Supuran CT, Monti SM, De Simone G, Di Fiore A
* Exploring benzoxaborole derivatives as carbonic anhydrase inhibitors: a structural and computational analysis reveals their conformational variability as a tool to increase enzyme selectivity (201 visite)
J Enzym Inhib Med Ch (ISSN: 1475-6366linking, 1475-6374electronic), 2019 Dec; 34(1): 1498-1505.
Impact Factor: 4.027
Dettagli Esporta in BibTeX Esporta in EndNote
Buemi MR, Di Fiore A, De Luca L, Angeli A, Mancuso F, Ferro S, Monti SM, Buonanno M, Russo E, De Sarro G, De Simone G, Supuran CT, Gitto R
* Exploring structural properties of potent human carbonic anhydrase inhibitors bearing a 4-(cycloalkylamino-1-carbonyl)benzenesulfonamide moiety (265 visite)
Eur J Med Chem (ISSN: 1768-3254electronic, 0223-5234linking), 2019 Feb 1; 163: 443-452.
Impact Factor: 4.833
Dettagli Esporta in BibTeX Esporta in EndNote
De Simone G
* Targeted treatment of anaerobic cancer. Patent evaluation of US2016279084 and US2017056350 (193 visite)
Expert Opin Ther Pat (ISSN: 1744-7674electronic, 1354-3776linking), 2019 Jan; 29(1): 1-6.
Impact Factor: 3.699
Dettagli Esporta in BibTeX Esporta in EndNote
Alterio V, Esposito D, Monti SM, Supuran CT, De Simone G
* Crystal structure of the human carbonic anhydrase II adduct with 1-(4-sulfamoylphenyl-ethyl)-2, 4, 6-triphenylpyridinium perchlorate, a membrane-impermeant, isoform selective inhibitor (498 visite)
J Enzym Inhib Med Ch (ISSN: 1475-6374electronic, 1475-6366linking), 2018 Dec; 33(1): 151-157.
Impact Factor: 4.293
Dettagli Esporta in BibTeX Esporta in EndNote
Monti SM, Meccariello A, Ceruso M, Szafranski K, Slawinski J, Supuran CT
* Inhibition studies of Brucella suis beta-carbonic anhydrases with a series of 4-substituted pyridine-3-sulphonamides (320 visite)
J Enzym Inhib Med Ch (ISSN: 1475-6374electronic, 1475-6366linking), 2018 Dec; 33(1): 255-259.
Impact Factor: 2.332
Dettagli Esporta in BibTeX Esporta in EndNote
Angeli A, Buonanno M, Donald WA, Monti SM, Supuran CT
* The zinc - but not cadmium - containing zeta-carbonic from the diatom Thalassiosira weissflogii is potently activated by amines and amino acids (136 visite)
Bioorg Chem (ISSN: 1090-2120electronic, 0045-2068linking), 2018 Oct; 80: 261-265.
Impact Factor: 3.929
Dettagli Esporta in BibTeX Esporta in EndNote
De Simone G, Angeli A, Bozdag M, Supuran CT, Winum JY, Monti SM, Alterio V
* Inhibition of carbonic anhydrases by a substrate analog: benzyl carbamate directly coordinates the catalytic zinc ion mimicking bicarbonate binding (218 visite)
Chem Commun (ISSN: 1364-548xelectronic, 1359-7345linking), 2018 Sep 11; 54(73): 10312-10315.
Impact Factor: 6.169
Dettagli Esporta in BibTeX Esporta in EndNote
Langella E, Buonanno M, Vullo D, Dathan N, Leone M, Supuran C, De Simone G, Monti SM
* Biochemical, biophysical and molecular dynamics studies on the proteoglycan-like domain of carbonic anhydrase IX (285 visite)
Cell Mol Life Sci (ISSN: 1420-682xlinking), 2018 Sep; 75(17): 3283-3296.
Impact Factor: 6.721
Dettagli Esporta in BibTeX Esporta in EndNote
Supuran CT, Alterio V, Di Fiore A, D'Ambrosio K, Carta F, Monti SM, De Simone G
* Inhibition of carbonic anhydrase IX targets primary tumors, metastases, and cancer stem cells: Three for the price of one (260 visite)
Med Res Rev (ISSN: 1098-1128electronic, 0198-6325linking), 2018 Sep; 38(6): 1799-1836.
Impact Factor: 8.29
Dettagli Esporta in BibTeX Esporta in EndNote
Mishra CB, Kumari S, Angeli A, Bua S, Buonanno M, Monti SM, Tiwari M, Supuran CT
* Discovery of potent anti-convulsant carbonic anhydrase inhibitors: Design, synthesis, in vitro and in vivo appraisal (203 visite)
Eur J Med Chem (ISSN: 0223-5234linking, 1768-3254electronic), 2018 Aug 5; 156: 430-443.
Impact Factor: 4.816
Dettagli Esporta in BibTeX Esporta in EndNote
Di Fiore A, Monti DM, Scaloni A, De Simone G, Monti SM
* Protective Role of Carbonic Anhydrases III and VII in Cellular Defense Mechanisms upon Redox Unbalance (183 visite)
Oxid Med Cell Longev (ISSN: 1942-0994linking), 2018 Aug 5; 2018:2018306: 2018306-2018306.
Impact Factor: 4.936
Dettagli Esporta in BibTeX Esporta in EndNote
Buonanno M, Di Fiore A, Langella E, D’ambrosio K, Supuran CT, Monti SM, De Simone G
* The Crystal Structure of a hCA VII Variant Provides Insights into the Molecular Determinants Responsible for Its Catalytic Behavior (225 visite)
Int J Mol Sc (ISSN: 1661-6596, 1422-0067, 1422-0067electronic), 2018 May; 19(6): 19-24.
Impact Factor: 3.687
Dettagli Esporta in BibTeX Esporta in EndNote
D'Ambrosio K, Supuran CT, De Simone G
* Are Carbonic Anhydrases Suitable Targets to Fight Protozoan Parasitic Diseases? (217 visite)
Curr Med Chem (ISSN: 1875-533xelectronic, 0929-8673linking), 2018; 25(39): 5266-5278.
Impact Factor: 4.63
Dettagli Esporta in BibTeX Esporta in EndNote
De Simone G, Langella E, Esposito D, Supuran CT, Monti SM, Winum JY, Alterio V
* Insights into the binding mode of sulphamates and sulphamides to hCA II: crystallographic studies and binding free energy calculations (218 visite)
J Enzym Inhib Med Ch (ISSN: 1475-6366, 1475-6374electronic, 1475-6366linking), 2017 Dec; 32(1): 1002-1011.
Impact Factor: 3.638
Dettagli Esporta in BibTeX Esporta in EndNote
Monti DM, De Simone G, Langella E, Supuran CT, Di Fiore A, Monti SM
* Insights into the role of reactive sulfhydryl groups of Carbonic Anhydrase III and VII during oxidative damage (326 visite)
J Enzym Inhib Med Ch (ISSN: 1475-6366, 1475-6374electronic, 1475-6366linking), 2017 Dec; 32(1): 5-12.
Impact Factor: 3.638
Dettagli Esporta in BibTeX Esporta in EndNote
Taskinen MR, Soderlund S, Bogl LH, Hakkarainen A, Matikainen N, Pietilainen KH, Rasanen S, Lundbom N, Bjornson E, Eliasson B, Mancina RM, Romeo S, Almeras N, Della Pepa G, Vetrani C, Prinster A, Annuzzi G, Rivellese A, Despres JP, Boren J
* Adverse effects of fructose on cardiometabolic risk factors and hepatic lipid metabolism in subjects with abdominal obesity (293 visite)
J Intern Med (ISSN: 0954-6820), 2017 May 26; N/D: N/D-N/D.
Impact Factor: 6.754
Dettagli Esporta in BibTeX Esporta in EndNote
Brunò E, Buemi MR, Di Fiore A, De LucaL, Ferro S, Angeli A, Cirilli R, Sadutto D, Alterio V, Monti SM, Supuran CT, De Simone G, Gitto R
* Probing Molecular Interactions between Human Carbonic Anhydrases (hCAs) and a Novel Class of Benzenesulfonamides (351 visite)
J Med Chem (ISSN: 0022-2623, 1520-4804, 0022-2623print), 2017 May 25; 60(10): 4316-4326.
Impact Factor: 6.253
Dettagli Esporta in BibTeX Esporta in EndNote
Buonanno M, Langella E, Zambrano N, Succoio M, Sasso E, Alterio V, Di Fiore A, Sandomenico A, Supuran CT, Scaloni A, Monti SM, De Simone G
* Disclosing the Interaction of Carbonic Anhydrase IX with Cullin-Associated NEDD8-Dissociated Protein 1 by Molecular Modeling and Integrated Binding Measurements (245 visite)
Acs Chem Biol (ISSN: 1554-8929), 2017 Apr 19; N/D: N/D-N/D.
Impact Factor: 4.592
Dettagli Esporta in BibTeX Esporta in EndNote
Mishra CB, Kumari S, Angeli A, Monti SM, Buonanno M, Tiwari M, Supuran CT
* Discovery of Benzenesulfonamides with Potent Human Carbonic Anhydrase Inhibitory and Effective Anticonvulsant Action: Design, Synthesis, and Pharmacological Assessment (306 visite)
J Med Chem (ISSN: 0022-2623, 1520-4804, 0022-2623print), 2017 Mar 23; 60(6): 2456-2469.
Impact Factor: 6.253
Dettagli Esporta in BibTeX Esporta in EndNote
Altug C, Gunes H, Nocentini A, Monti SM, Buonanno M, Supuran CT
* Synthesis of isoxazole-containing sulfonamides with potent carbonic anhydrase II and VII inhibitory properties (254 visite)
Bioorg Med Chem (ISSN: 0968-0896, 1464-3391), 2017 Feb 15; 25(4): 1456-1464.
Impact Factor: 2.881
Dettagli Esporta in BibTeX Esporta in EndNote
Angapelly S, Ramya PV, Angeli A, Monti SM, Buonanno M, Alvala M, Supuran CT, Arifuddin M
* Discovery of 4-sulfamoyl-phenyl-beta-lactams as a new class of potent carbonic anhydrase isoforms I, II, IV and VII inhibitors: The first example of subnanomolar CA IV inhibitors (274 visite)
Bioorg Med Chem (ISSN: 0968-0896, 1464-3391), 2017 Jan 15; pii:S0968-0896(16): 539-544.
Impact Factor: 2.881
Dettagli Esporta in BibTeX Esporta in EndNote
Angapelly S, Ramya PVS, Angeli A, Monti SM, Buonanno M, Alvala M, Supuran CT, Arifuddin M
* Discovery of 4-sulfamoyl-phenyl-β-lactams as a new class of potent carbonic anhydrase isoforms I, II, IV and VII inhibitors: The first example of subnanomolar CA IV inhibitors (218 visite)
Bioorg Med Chem (ISSN: 0968-0896, 1464-3391), 2017; 25(2): 539-544.
Impact Factor: 2.881
Dettagli Esporta in BibTeX Esporta in EndNote
Bozzetto L, Costabile G, Luongo D, Naviglio D, Cicala V, Piantadosi C, Patti L, Cipriano P, Annuzzi G, Rivellese AA
* Reduction in liver fat by dietary MUFA in type 2 diabetes is helped by enhanced hepatic fat oxidation (185 visite)
Diabetologia (ISSN: 0012-186x), 2016 Dec; 59(12): 2697-2701.
Impact Factor: 6.08
Dettagli Esporta in BibTeX Esporta in EndNote
Alterio V, Cadoni R, Esposito D, Vullo D, Fiore AD, Monti SM, Caporale A, Ruvo M, Sechi M, Dumy P, Supuran CT, De Simone G, Winum JY
* Benzoxaborole as a new chemotype for carbonic anhydrase inhibition (326 visite)
Chem Commun (ISSN: 1359-7345, 1364-548x, 1364-548xelectronic), 2016 Sep 29; 52(80): 11983-11986.
Impact Factor: 6.319
Dettagli Esporta in BibTeX Esporta in EndNote
Vullo D, Supuran CT, Scozzafava A, De Simone G, Monti SM, Alterio V, Carta F
* Kinetic and X-ray crystallographic investigations of substituted 2-thio-6-oxo-1, 6-dihydropyrimidine-benzenesulfonamides acting as carbonic anhydrase inhibitors (222 visite)
Bioorg Med Chem (ISSN: 0968-0896, 1464-3391), 2016 Aug 15; 24(16): 3643-3648.
Impact Factor: 2.93
Dettagli Esporta in BibTeX Esporta in EndNote
Di Fiore A, De Simone G, Alterio V, Riccio V, Winum JY, Carta F, Supuran CT
* The anticonvulsant sulfamide JNJ-26990990 and its S, S-dioxide analog strongly inhibit carbonic anhydrases: solution and X-ray crystallographic studies (213 visite)
Org Biomol Chem (ISSN: 1477-0520, 1477-0539, 1477-0539electronic), 2016 Jun 07; 14(21): 4853-4858.
Impact Factor: 3.564
Dettagli Esporta in BibTeX Esporta in EndNote
Del Prete S, De Luca V, De Simone G, Supuran CT, Capasso C
* Cloning, expression and purification of the complete domain of the eta-carbonic anhydrase from Plasmodium falciparum (325 visite)
J Enzym Inhib Med Ch (ISSN: 1475-6366, 1475-6374electronic, 1475-6366linking), 2016 Jun; 31(sup4): 54-59.
Impact Factor: 4.293
Dettagli Esporta in BibTeX Esporta in EndNote
Langella E, D'Ambrosio K, D'Ascenzio M, Carradori S, Monti SM, Supuran CT, De Simone G
* A Combined Crystallographic and Theoretical Study Explains the Capability of Carboxylic Acids to Adopt Multiple Binding Modes in the Active Site of Carbonic Anhydrases (285 visite)
Chemistry (ISSN: 0947-6539, 1521-3765, 1521-3765electronic), 2016 Jan 4; 22(1): 97-100.
Impact Factor: 5.317
Dettagli Esporta in BibTeX Esporta in EndNote
Mishra CB, Kumari S, Angeli A, Monti SM, Buonanno M, Prakash A, Tiwari M, Supuran CT
* Design, synthesis and biological evaluation of N-(5-methyl-isoxazol-3-yl/1, 3, 4-thiadiazol-2-yl)-4-(3-substitutedphenylureido) benzenesulfonamides as human carbonic anhydrase isoenzymes I, II, VII and XII inhibitors (257 visite)
J Enzyme Inhib Med Chem, 2016; 17: 1-6.
Impact Factor: 3.428
Dettagli Esporta in BibTeX Esporta in EndNote
Mollica A, Locatelli M, Macedonio G, Carradori S, Sobolev AP, De Salvador RF, Monti SM, Buonanno M, Zengin G, Angeli A, Supuran CT
* Microwave-assisted extraction, HPLC analysis, and inhibitory effects on carbonic anhydrase I, II, VA, and VII isoforms of 14 blueberry Italian cultivars (212 visite)
J Enzyme Inhib Med Chem, 2016; 31(sup4): N/D-N/D.
Impact Factor: 3.428
Dettagli Esporta in BibTeX Esporta in EndNote
La Regina G, Coluccia A, Famiglini V, Pelliccia S, Monti L, Vullo D, Nuti E, Alterio V, De Simone G, Monti SM, Pan P, Parkkila S, Supuran CT, Rossello A, Silvestri R
* Discovery of 1, 1'-Biphenyl-4-sulfonamides as a New Class of Potent and Selective Carbonic Anhydrase XIV Inhibitors (287 visite)
J Med Chem (ISSN: 0022-2623, 1520-4804, 0022-2623print), 2015 Nov 12; 58(21): 8564-8572.
Impact Factor: 5.589
Dettagli Esporta in BibTeX Esporta in EndNote
Di Fiore A, Vergara A, Caterino M, Alterio V, Monti SM, Ombouma J, Dumy P, Vullo D, Supuran CT, Winum JY, De Simone G
* Hydroxylamine-O-sulfonamide is a versatile lead compound for the development of carbonic anhydrase inhibitors (284 visite) (PDF 208 visite)
Chem Commun (ISSN: 1359-7345, 1364-548x, 1364-548xelectronic), 2015 Jul 2; 51(57): 11519-11522.
Impact Factor: 6.567
Dettagli Esporta in BibTeX Esporta in EndNote
De Simone G, Monti SM, Alterio V, Buonanno M, De Luca V, Rossi M, Carginale V, Supuran CT, Capasso C, Di Fiore A
* Crystal structure of the most catalytically effective carbonic anhydrase enzyme known, SazCA from the thermophilic bacterium Sulfurihydrogenibium azorense (249 visite)
Bioorg Med Chem Lett (ISSN: 0960-894x), 2015 May 1; 25(9): 2002-2006.
Impact Factor: 2.486
Dettagli Esporta in BibTeX Esporta in EndNote
Alterio V, Tanc M, Ivanova J, Zalubovskis R, Vozny I, Monti SM, Di Fiore A, De Simone G, Supuran CT
* X-ray crystallographic and kinetic investigations of 6-sulfamoyl-saccharin as a carbonic anhydrase inhibitor (306 visite)
Org Biomol Chem (ISSN: 1477-0520, 1477-0539, 1477-0539electronic), 2015 Apr 7; 13(13): 4064-4069.
Impact Factor: 3.559
Dettagli Esporta in BibTeX Esporta in EndNote
De Simone G, Di Fiore A, Capasso C, Supuran CT
* The zinc coordination pattern in the eta-carbonic anhydrase from Plasmodium falciparum is different from all other carbonic anhydrase genetic families (433 visite)
Bioorg Med Chem Lett (ISSN: 0960-894x), 2015 Apr 1; 25(7): 1385-1389.
Impact Factor: 2.486
Dettagli Esporta in BibTeX Esporta in EndNote
Alterio V, Langella E, De Simone G, Monti SM
* Cadmium-containing carbonic anhydrase CDCA1 in marine diatom Thalassiosira weissflogii (428 visite)
Mar Drugs (ISSN: 1660-3397, 1660-3397linking), 2015 Mar 25; 13(4): 1688-1697.
Impact Factor: 3.345
Dettagli Esporta in BibTeX Esporta in EndNote
Monti SM, Supuran CT, De Simone G
* DPP-4 inhibitors: a patent review (2012 - 2014) (337 visite)
Expert Opin Ther Pat (ISSN: 1354-3776, 1744-7674electronic), 2015 Feb; 25(2): 209-236.
Impact Factor: 4.626
Dettagli Esporta in BibTeX Esporta in EndNote
Supuran CT, Capasso C, De Simone G
* Carbonic Anhydrase II as Target for Drug Design (235 visite)
Carbonic Anhydrases As Biocatalysts, 2015 Jan 08; N/D: 51-90.
Impact Factor: 0
Dettagli Esporta in BibTeX Esporta in EndNote
Monti SM, Supuran CT, De Simone G, Di Fiore A
* Carbonic Anhydrase VII (187 visite)
Carbonic Anhydrases As Biocatalysts, 2015 Jan 08; N/D: 151-168.
Impact Factor: 0
Dettagli Esporta in BibTeX Esporta in EndNote
Supuran CT, De Simone G
Carbonic Anhydrases: An Overview (207 visite)
Carbonic Anhydrases As Biocatalysts, 2015 Jan 08; N/D: 3-13.
Impact Factor: 0
Dettagli Esporta in BibTeX Esporta in EndNote
D'Ambrosio K, De Simone G, Supuran CT
* Human Carbonic Anhydrases: Catalytic Properties, Structural Features, and Tissue Distribution (251 visite)
Carbonic Anhydrases As Biocatalysts, 2015 Jan 08; N/D: 17-30.
Impact Factor: 0
Dettagli Esporta in BibTeX Esporta in EndNote
D'Ambrosio K, Carradori S, Monti SM, Buonanno M, Secci D, Vullo D, Supuran CT, De Simone G
* Out of the active site binding pocket for carbonic anhydrase inhibitors (341 visite) (PDF 228 visite)
Chem Commun (ISSN: 1359-7345, 1364-548x, 1364-548xelectronic), 2015 Jan 7; 51(2): 302-305.
Impact Factor: 6.567
Dettagli Esporta in BibTeX Esporta in EndNote
Ceruso M, Carta F, Osman SM, Alothman Z, Monti SM, Supuran CT
* Inhibition studies of bacterial, fungal and protozoan β-class carbonic anhydrases with Schiff bases incorporating sulfonamide moieties (326 visite)
Bioorg Med Chem (ISSN: 0968-0896, 1464-3391), 2015; 23(15): 4181-4187.
Impact Factor: 2.923
Dettagli Esporta in BibTeX Esporta in EndNote
Iqbal J, Al-rashida M, Durdagi S, Alterio V, Di Fiore A
* Recent developments of carbonic anhydrase inhibitors as potential drugs (377 visite)
Biomed Res Int (ISSN: 2314-6133, 2314-6141), 2015; 2015: 174178-174178.
Impact Factor: 2.134
Dettagli Esporta in BibTeX Esporta in EndNote
Di Fiore A, Alterio V, Monti SM, De Simone G, D’Ambrosio K
* Thermostable carbonic anhydrases in biotechnological applications (407 visite)
Int J Mol Sc (ISSN: 1422-0067, 1661-6596, 1422-0067linking), 2015; 16(7): 15456-15480.
Impact Factor: 3.257
Dettagli Esporta in BibTeX Esporta in EndNote
De Simone R, Ranieri A, Montella S, Cappabianca P, Quarantelli M, Esposito F, Cardillo G, Bonavita V
* Intracranial pressure in unresponsive chronic migraine (369 visite)
J Neurol (ISSN: 0340-5354, 1432-1459, 0340-5354print), 2014 Jul; 261(7): 1365-1373.
Impact Factor: 3.377
Dettagli Esporta in BibTeX Esporta in EndNote
Bilo L, Peluso S, Antenora A, De Rosa A, Auletta G, Pappata S, De Michele G
* Parkinsonism may be part of the symptom complex of DOOR syndrome (220 visite)
Parkinsonism Relat D (ISSN: 1353-8020, 1873-5126, 1353-8020print), 2014 Apr; 20(4): 463-465.
Impact Factor: 3.972
Dettagli Esporta in BibTeX Esporta in EndNote
Dathan NA, Alterio V, Troiano E, Vullo D, Ludwig M, De Simone G, Supuran CT, Monti SM
* Biochemical Characterization Of The Chloroplastic β-Carbonic Anhydrase From Flaveria Bidentis (l. ) "kuntze" (346 visite)
J Enzym Inhib Med Ch (ISSN: 1475-6366, 1475-6374electronic, 1475-6366linking), 2014; 29(4): 500-504.
Impact Factor: 2.332
Dettagli Esporta in BibTeX Esporta in EndNote
De Simone G, Pizika G, Monti SM, Di Fiore A, Ivanova J, Vozny I, Trapencieris P, Zalubovskis R, Supuran CT, Alterio V
* Hydrophobic substituents of the phenylmethylsulfamide moiety can be used for the development of new selective carbonic anhydrase inhibitors (309 visite)
Biomed Res Int (ISSN: 2314-6133, 2314-6141), 2014; 2014: 523210-523210.
Impact Factor: 1.579
Dettagli Esporta in BibTeX Esporta in EndNote
Alterio V, Pan P, Parkkila S, Buonanno M, Supuran CT, Monti SM, De Simone G
* The Structural Comparison Between Membrane-Associated Human Carbonic Anhydrases Provides Insights Into Drug Design Of Selective Inhibitors (370 visite)
Biopolymers (ISSN: 0006-3525, 0006-6352, 0006-3525print), 2014; 101(7): 769-778.
Impact Factor: 2.385
Dettagli Esporta in BibTeX Esporta in EndNote
Alterio V, Monti SM, De Simone G
* Thermal-stable carbonic anhydrases: a structural overview (346 visite)
Subcell Biochem (ISSN: 0306-0225), 2014; 75: 387-404.
Impact Factor: 33.116
Dettagli Esporta in BibTeX Esporta in EndNote
Pedone C, Napoli N, Pozzilli P, Lauretani F, Bandinelli S, Ferrucci L, Rossi FF, Antonelli Incalzi R
* Bone health as a function of adipokines and vitamin D pattern in elderly patients (258 visite)
Rejuv Res (ISSN: 1557-8577, 1549-1684), 2013 Dec; 16(6): 467-474.
Impact Factor: 3.931
Dettagli Esporta in BibTeX Esporta in EndNote
Rami M, Dubois L, Parvathaneni NK, Alterio V, van Kuijk SJ, Monti SM, Lambin P, De Simone G, Supuran CT, Winum JY
* Hypoxia-targeting carbonic anhydrase IX inhibitors by a new series of nitroimidazole-sulfonamides/sulfamides/sulfamates (471 visite)
J Med Chem (ISSN: 0022-2623, 1520-4804, 0022-2623print), 2013 Nov 14; 56(21): 8512-8520.
Impact Factor: 5.48
Dettagli Esporta in BibTeX Esporta in EndNote
De Simone G, Alterio V, Supuran CT
* Exploiting the hydrophobic and hydrophilic binding sites for designing carbonic anhydrase inhibitors (376 visite)
Expert Opin Drug Discov (ISSN: 1746-0441), 2013 Jul; 8(7): 793-810.
Impact Factor: 3.467
Dettagli Esporta in BibTeX Esporta in EndNote
Monti SM, Supuran CT, De Simone G
* Anticancer carbonic anhydrase inhibitors: A patent review (2008-2013) (379 visite)
Expert Opin Ther Pat (ISSN: 1354-3776, 1744-7674electronic), 2013 Jun; 23(6): 737-749.
Impact Factor: 3.441
Dettagli Esporta in BibTeX Esporta in EndNote
Di Fiore A, Capasso C, De Luca V, Monti SM, Carginale V, Supuran CT, Scozzafava A, Pedone C, Rossi M, De Simone G
* X-ray structure of the first 'extremo-alpha-carbonic anhydrase', a dimeric enzyme from the thermophilic bacterium Sulfurihydrogenibium yellowstonense YO3AOP1 (377 visite)
Acta Crystallogr D Biol Crystallogr (ISSN: 0907-4449, 0907-4449linking), 2013 Jun; 69(6): 1150-1159.
Impact Factor: 7.232
Dettagli Esporta in BibTeX Esporta in EndNote
Monti SM, De Simone G, Dathan NA, Ludwig M, Vullo D, Scozzafava A, Capasso C, Supuran CT
* Kinetic And Anion Inhibition Studies Of A Beta-Carbonic Anhydrase (fbica 1) From The C-4 Plant Flaveria Bidentis (384 visite)
Bioorg Med Chem Lett (ISSN: 0960-894x), 2013 Mar 15; 23(6): 1626-1630.
Impact Factor: 2.331
Dettagli Esporta in BibTeX Esporta in EndNote
Buanne P, Renzone G, Monteleone F, Vitale M, Monti SM, Sandomenico A, Garbi C, Montanaro D, Accardo M, Troncone G, Zatovicova M, Csaderova L, Supuran CT, Pastorekova S, Scaloni A, De Simone G, Zambrano N
* Characterization of carbonic anhydrase ix interactome reveals proteins assisting its nuclear localization in hypoxic cells (338 visite)
J Proteome Res (ISSN: 1535-3893), 2013 Jan; 12(1): 282-292.
Impact Factor: 5.001
Dettagli Esporta in BibTeX Esporta in EndNote
Del Giudice R, Monti DM, Truppo E, Arciello A, Supuran CT, De Simone G, Monti SM
* Human Carbonic Anhydrase Vii Protects Cells From Oxidative Damage (320 visite)
Biol Chem Biological Chemistry (ISSN: 1431-6730, 1431-1673, 1437-4315), 2013; 394(10): 1343-1348.
Impact Factor: 2.689
Dettagli Esporta in BibTeX Esporta in EndNote
Alterio V, Di Fiore A, D'Ambrosio K, Supuran CT, De Simone G
* Multiple binding modes of inhibitors to carbonic anhydrases: How to design specific drugs targeting 15 different isoforms? (385 visite)
Chem Rev (ISSN: 0009-2665), 2012 Sep; 112(8): 4421-4468.
Impact Factor: 41.298
Dettagli Esporta in BibTeX Esporta in EndNote
De Simone G, Supuran CT
* (In)organic anions as carbonic anhydrase inhibitors (342 visite)
J Chem Res (ISSN: 0162-0134, 1873-3344, 0162-0134print), 2012 Jun; 111: 117-129.
Impact Factor: 3.197
Dettagli Esporta in BibTeX Esporta in EndNote
Alterio V, Langella E, Viparelli F, Vullo D, Ascione G, Dathan NA, Morel FM, Supuran CT, De Simone G, Monti SM
* Structural and inhibition insights into carbonic anhydrase CDCA1 from the marine diatom Thalassiosira weissflogii (371 visite)
Biochimie (ISSN: 0300-9084, 1638-6183, 1638-6183electronic), 2012 May; 94(5): 1232-1241.
Impact Factor: 3.142
Dettagli Esporta in BibTeX Esporta in EndNote
Truppo E, Supuran CT, Sandomenico A, Vullo D, Innocenti A, Di Fiore A, Alterio V, De Simone G, Monti SM
* Carbonic anhydrase VII is S-glutathionylated without loss of catalytic activity and affinity for sulfonamide inhibitors (333 visite)
Bioorg Med Chem Lett Bioorganic And Medicinal Chemistry Letters (ISSN: 0960-894x), 2012 Feb 15; 22(4): 1560-1564.
Impact Factor: 2.338
Dettagli Esporta in BibTeX Esporta in EndNote
Monti SM, Supuran CT, De Simone G
* Carbonic anhydrase IX as a target for designing novel anticancer drugs (415 visite)
Curr Med Chem (ISSN: 0929-8673, 1875-533x, 1875-533xelectronic), 2012 Feb; 19(6): 821-830.
Impact Factor: 4.07
Dettagli Esporta in BibTeX Esporta in EndNote
De Simone G
* Editorial: Zinc Metallo-Enzymes As Target For Drug Design (338 visite)
Curr Med Chem (ISSN: 0929-8673, 1875-533x, 1875-533xelectronic), 2012 Feb; 19(6): 820-1012.
Impact Factor: 4.07
Dettagli Esporta in BibTeX Esporta in EndNote
Monti SM, Maresca A, Viparelli F, Carta F, De Simone G, Muehlschlegel FA, Scozzafava A, Supuran CT
* Dithiocarbamates are strong inhibitors of the beta-class fungal carbonic anhydrases from Cryptococcus neoformans, Candida albicans and Candida glabrata (330 visite)
Bioorg Med Chem Lett (ISSN: 0960-894x), 2012 Jan 15; 22(2): 859-862.
Impact Factor: 2.338
Dettagli Esporta in BibTeX Esporta in EndNote
D'Ambrosio K, Smaine F-Z, Carta F, De Simone G, Winum J-Y, Supuran CT
* Development of potent carbonic anhydrase inhibitors incorporating both sulfonamide and sulfamide groups (406 visite)
J Med Chem (ISSN: 0022-2623, 1520-4804, 0022-2623print), 2012; 55(15): 6776-6783.
Impact Factor: 5.614
Dettagli Esporta in BibTeX Esporta in EndNote
Di Fiore A, Maresca A, Supuran CT, De Simone G
* Hydroxamate represents a versatile zinc binding group for the development of new carbonic anhydrase inhibitors (316 visite)
Chem Commun (ISSN: 1359-7345, 1364-548x, 1364-548xelectronic), 2012; 48(70): 8838-8840.
Impact Factor: 6.378
Dettagli Esporta in BibTeX Esporta in EndNote
Di Fiore A, Maresca A, Alterio V, Supuran CT, De Simone G
* Carbonic anhydrase inhibitors: X-ray crystallographic studies for the binding of N-substituted benzenesulfonamides to human isoform II (314 visite)
Chem Commun (ISSN: 1359-7345, 1364-548x, 1364-548xelectronic), 2011; 47(42): 11636-11638.
Impact Factor: 6.169
Dettagli Esporta in BibTeX Esporta in EndNote
Viparelli F, Monti SM, De Simone G, Innocenti A, Scozzafava A, Xu Y, Morel FMM, Supuran CT
* Inhibition Of The R1 Fragment Of The Cadmium-Containing Zeta-Class Carbonic Anhydrase From The Diatom Thalassiosira Weissflogii With Anions (296 visite)
Bioorganic & Medicinal Chemistry Letters (ISSN: 0960-894x), 2010 Sep 15; 20(16): 4745-4748.
Impact Factor: 2.661
Dettagli Esporta in BibTeX Esporta in EndNote
Alterio V, Monti SM, Truppo E, Pedone C, Supuran CT, De Simone G
* The first example of a significant active site conformational rearrangement in a carbonic anhydrase-inhibitor adduct: The carbonic anhydrase I-topiramate complex (359 visite)
Org Biomol Chem (ISSN: 1477-0520, 1477-0539, 1477-0539electronic), 2010 Sep 7; 8(15): 3528-3533.
Impact Factor: 3.451
Dettagli Esporta in BibTeX Esporta in EndNote
Di Fiore A, Truppo E, Supuran CT, Alterio V, Dathan N, Bootorabi F, Parkkila S, Monti SM, De Simone G
* Crystal structure of the C183S/C217S mutant of human CA VII in complex with acetazolamide (276 visite)
Bioorg Med Chem Lett (ISSN: 0960-894x), 2010 Sep 1; 20(17): 5023-5026.
Impact Factor: 2.661
Dettagli Esporta in BibTeX Esporta in EndNote
Di Fiore A, Monti SM, Innocenti A, Winum J-Y, De Simone G, Supuran CT
* Carbonic anhydrase inhibitors: Crystallographic and solution binding studies for the interaction of a boron-containing aromatic sulfamide with mammalian isoforms I-XV (304 visite)
Bioorg Med Chem Lett Bioorganic And Medicinal Chemistry Letters (ISSN: 0960-894x), 2010 Jun 15; 20(12): 3601-3605.
Impact Factor: 2.661
Dettagli Esporta in BibTeX Esporta in EndNote
De Simone G, Supuran CT
* Carbonic anhydrase IX: Biochemical and crystallographic characterization of a novel antitumor target (354 visite)
Bba-Gen Subjects (ISSN: 1570-9639, 0006-3002, 0925-4439), 2010 Feb; 1804(2): 404-409.
Impact Factor: 2.773
Dettagli Esporta in BibTeX Esporta in EndNote
Guler OO, De Simone G, Supuran CT
* Drug design studies of the novel antitumor targets carbonic anhydrase IX and XII (430 visite)
Curr Med Chem (ISSN: 0929-8673, 1875-533x, 1875-533xelectronic), 2010; 17(15): 1516-1526.
Impact Factor: 4.63
Dettagli Esporta in BibTeX Esporta in EndNote
Supuran CT, Di Fiore A, Alterio V, Monti SM, De Simone G
* Recent advances in structural studies of the carbonic anhydrase family: The crystal structure of human CA IX and CA XIII (398 visite)
Curr Pharm Des Current Pharmaceutical Design (ISSN: 1381-6128, 1873-4286), 2010; 16(29): 3246-3254.
Impact Factor: 4.774
Dettagli Esporta in BibTeX Esporta in EndNote
Kapucu OL, Nobili F, Varrone A, Booij J, Vander Borght T, Nagren K, Darcourt J, Tatsch K, Van Laere KJ
* EANM procedure guideline for brain perfusion SPECT using Tc-99m-labelled radiopharmaceuticals, version (444 visite)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2009 Dec; 36(12): 2093-2102.
Impact Factor: 4.531
Dettagli Esporta in BibTeX Esporta in EndNote
Innocenti A, Pastorekova S, Pastorek J, Scozzafava A, De Simone G, Supuran CT
* The proteoglycan region of the tumor-associated carbonic anhydrase isoform IX acts as anintrinsic buffer optimizing CO2 hydration at acidic pH values characteristic of solid tumors (209 visite)
Bioorganic & Medicinal Chemistry Letters (ISSN: 0960-894x), 2009 Oct 15; 19(20): 5825-5828.
Impact Factor: 2.65
Dettagli Esporta in BibTeX Esporta in EndNote
Vitale RM, Alterio V, Innocenti A, Winum JY, Monti SM, De Simone G, Supuran CT
* Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis- sulfamate adducts with isozymes II and IX as a platform for designing tight-binding, more isoform-selective inhibitors (390 visite)
J Med Chem (ISSN: 0022-2623, 1520-4804, 0022-2623print), 2009 Oct 8; 52(19): 5990-5998.
Impact Factor: 4.802
Dettagli Esporta in BibTeX Esporta in EndNote
Alterio V, Hilvo M, Di Fiore A, Supuran CT, Pan P, Parkkila S, Scaloni A, Pastorek J, Pastorekova S, Pedone C, Scozzafava A, Monti SM, De Simone G
* Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX (472 visite)
P Natl Acad Sci Usa (ISSN: 0027-8424, 1091-6490, 0027-8424print), 2009 Sep 22; 106(38): 16233-16238.
Impact Factor: 9.432
Dettagli Esporta in BibTeX Esporta in EndNote
Coppola G, Fortunato D, Auricchio G, Mainolfi C, Operto FF, Signoriello G, Pascotto A, Salvatore M
* Bone mineral density in children, adolescents, and young adults with epilepsy (321 visite)
Epilepsia (ISSN: 1528-1167, 0013-9580), 2009 Sep; 50(9): 2140-2146.
Impact Factor: 4.052
Dettagli Esporta in BibTeX Esporta in EndNote
De Simone G, Scozzafava A, Supuran CT
* Which Carbonic Anhydrases are Targeted by the Antiepileptic Sulfonamides and Sulfamates? (301 visite)
Chem Biol Drug Des Chemical Biology And Drug Design (ISSN: 1747-0277, 1747-0285), 2009 Sep; 74(3): 317-321.
Impact Factor: 2.473
Dettagli Esporta in BibTeX Esporta in EndNote
Di Fiore A, Monti SM, Hilvo M, Parkkila S, Romano V, Scaloni A, Pedone C, Scozzafava A, Supuran CT, De Simone G
* Crystal structure of human carbonic anhydrase XIII and its complex with the inhibitor acetazolamide (406 visite)
Proteins (ISSN: 1097-0134, 0887-3585, 1097-0134electronic), 2009 Jan; 74(1): 164-175.
Impact Factor: 3.085
Dettagli Esporta in BibTeX Esporta in EndNote
Hilvo M, De Simone G, Supuran CT, Parkkila S
* Advances in the Inhibitory and Structural Investigations on Carbonic Anhydrase Isozymes XIII and XV (246 visite)
Drug Des Of Zinc Enzyme Inhibitors (ISSN: 9780-4702, 9780-470275009), 2009; N/D: 273-283.
Impact Factor: 1.156
Dettagli Esporta in BibTeX Esporta in EndNote
De Simone G, Supuran CT
* Drug Design of Antiobesity Carbonic Anhydrase Inhibitors (289 visite)
Drug Des Of Zinc Enzyme Inhibitors (ISSN: 9780-4702, 9780-470275009), 2009; 66(DECEMBERSPEC.I): 241-254.
Impact Factor: 1.156
Dettagli Esporta in BibTeX Esporta in EndNote
Alterio V, Di Fiore A, D'Ambrosio K, Supuran CT, De Simone G
* X-Ray Crystallography of Carbonic Anhydrase Inhibitors and Its Importance in Drug Design (315 visite)
Drug Des Of Zinc Enzyme Inhibitors (ISSN: 9780-4702, 9780-470275009), 2009; N/D: 73-138.
Impact Factor: 1.156
Dettagli Esporta in BibTeX Esporta in EndNote
Hilvo M, Baranauskiene L, Salzano AM, Scaloni A, Matulis D, Innocenti A, Scozzafava A, Monti SM, Di Fiore A, De Simone G, Lindfors M, Janis J, Valjakka J, Pastorekova S, Pastorek J, Kulomaa MS, Nordlund HR, Supuran CT, Parkkila S
* Biochemical characterization of CA IX, one of the most active carbonic anhydrase isozymes (381 visite)
Jbc Papers (ISSN: 0021-9258, 1083-351x, 0021-9258linking), 2008 Oct 10; 283(41): 27799-27809.
Impact Factor: 5.52
Dettagli Esporta in BibTeX Esporta in EndNote
D'Ambrosio K, Vitale R, Dogne J, Masereel B, Innocenti A, Scozzafava A, De Simone G, Supuran CT
* Ccarbonic Anhydrase Inhibitors: Bioreductive Nitro-Containing Sulfonamides With Selectivity For Targeting The Tumor Associated Isoforms Ix And Xii (435 visite)
J Med Chem (ISSN: 1520-4804, 0022-2623, 0022-2623print), 2008 Jun 12; 51(11): 3230-3237.
Impact Factor: 4.898
Dettagli Esporta in BibTeX Esporta in EndNote
Di Fiore A, Pedone C, Antel J, Waldeck H, Witte A, Wurl M, Scozzafava A, Supuran CT, De Simone G
* Carbonic anhydrase inhibitors: the X-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors (358 visite)
Bioorg Med Chem Lett (ISSN: 1464-3405, 0960-894x, 1464-3405electronic), 2008 Apr 15; 18(8): 2669-2674.
Impact Factor: 2.531
Dettagli Esporta in BibTeX Esporta in EndNote
Innocenti A, Scozzafava A, Parkkila S, Puccetti L, De Simone G, Supuran CT
* Investigations of the esterase, phosphatase, and sulfatase activities of the cytosolic mammalian carbonic anhydrase isoforms I, II, and XIII with 4-nitrophenyl esters as substrates (336 visite)
Bioorg Med Chem Lett Bioorganic And Medicinal Chemistry Letters (ISSN: 0960-894x), 2008 Apr 1; 18(7): 2267-2271.
Impact Factor: 2.531
Dettagli Esporta in BibTeX Esporta in EndNote
Leese MP, Jourdan FL, Gaukroger K, Mahon MF, Newman SP, Foster PA, Stengel C, Regis-Lydi S, Ferrandis E, Di Fiore A, De Simone G, Supuran CT, Purohit A, Reed MJ, Potter BVL
* Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents (380 visite)
J Med Chem (ISSN: 0022-2623, 1520-4804, 0022-2623print), 2008 Mar 13; 51(5): 1295-1308.
Impact Factor: 4.898
Dettagli Esporta in BibTeX Esporta in EndNote
De Simone G, Di Fiore A, Supuran CT
* Are carbonic anhydrase inhibitors suitable for obtaining antiobesity drugs? (356 visite)
Curr Pharm Des Current Pharmaceutical Design (ISSN: 1381-6128, 1873-4286), 2008 Mar; 14(7): 655-660.
Impact Factor: 4.399
Dettagli Esporta in BibTeX Esporta in EndNote
D'Ambrosio K, Masereel B, Thiry A, Scozzafava A, Supuran CT, De Simone G
* Carbonic anhydrase inhibitors: Binding of indanesulfonamides to the human isoform II (330 visite)
Chemmedchem (ISSN: 1860-7179, 1860-7187, 1860-7187electronic), 2008 Mar; 3(3): 473-477.
Impact Factor: 3.15
Dettagli Esporta in BibTeX Esporta in EndNote
Supuran CT, De Simone G
Carbonic anhydrases--an overview (315 visite)
Curr Pharm Des, 2008; 14(7): 603-614.
Impact Factor: 0
Dettagli Esporta in BibTeX Esporta in EndNote
Hilvo M, Innocenti A, Monti SM, De Simone G, Supuran CT, Parkkila S
* Recent advances in research on the most novel carbonic anhydrases, CA XIII and XV (326 visite)
Curr Pharm Des Current Pharmaceutical Design (ISSN: 1381-6128, 1873-4286), 2008; 14(7): 672-678.
Impact Factor: 4.399
Dettagli Esporta in BibTeX Esporta in EndNote
Alterio V, De Simone G, Monti SM, Scozzafava A, Supuran CT
* Carbonic anhydrase inhibitors: Inhibition of human, bacterial, and archaeal isozymes with benzene-1, 3-disulfonamides-Solution and crystallographic studies (301 visite)
Bioorg Med Chem Lett Bioorganic And Medicinal Chemistry Letters (ISSN: 0960-894x), 2007 Sep 1; 17(15): 4201-4207.
Impact Factor: 2.604
Dettagli Esporta in BibTeX Esporta in EndNote
Vitale RM, Pedone C, Amodeo P, Antel J, Wurl M, Scozzafava A, Supuran CT, De Simone G
* Molecular modeling study for the binding of zonisamide and topiramate to the human mitochondrial carbonic anhydrase isoform VA (308 visite)
Bioorg Med Chem (ISSN: 0968-0896, 1464-3391, 1464-3391electronic), 2007 Jun 15; 15(12): 4152-4158.
Impact Factor: 2.662
Dettagli Esporta in BibTeX Esporta in EndNote
Di Fiore A, Scozzafava A, Winum JY, Montero JL, Pedone C, Supuran CT, De Simone G
* Carbonic anhydrase inhibitors: binding of an antiglaucoma glycosyl-sulfanilamide derivative to human isoform II and its consequences for the drug design of enzyme inhibitors incorporating sugar moieties (384 visite)
Bioorg Med Chem Lett Bioorganic And Medicinal Chemistry Letters (ISSN: 0960-894x), 2007 Mar 15; 17(6): 1726-1731.
Impact Factor: 2.604
Dettagli Esporta in BibTeX Esporta in EndNote
De Simone G, Supuran CT
* Antiobesity carbonic anhydrase inhibitors (393 visite)
Curr Top Med Chem (ISSN: 1568-0266, 1568-0266linking, 1873-4294electronic), 2007; 7(9): 879-884.
Impact Factor: 4.325
Dettagli Esporta in BibTeX Esporta in EndNote
Leese MP, Leblond B, Smith A, Newman SP, Di Fiore A, De Simone G, Supuran CT, Purohit A, Reed MJ, Potter BVL
* 2-substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity (795 visite)
J Med Chem (ISSN: 0022-2623print, 0022-2623linking, 1520-4804), 2006 Dec 28; 49(26): 7683-7696.
Impact Factor: 5.115
Dettagli Esporta in BibTeX Esporta in EndNote
Menchise V, De Simone G, Di Fiore A, Scozzafava A, Supuran CT
* Carbonic anhydrase inhibitors: X-ray crystallographic studies for the binding of 5-amino-1, 3, 4-thiadiazole-2-sulfonamide and 5-(4-amino-3-chloro-5-fluorophenylsulfonamido)1, 3, 4-thiadiazole-2-sulfon amide to human isoform II (277 visite)
Bioorganic & Medicinal Chemistry Letters (ISSN: 0960-894x), 2006 Dec 15; 16(24): 6204-6208.
Impact Factor: 2.538
Dettagli Esporta in BibTeX Esporta in EndNote
De Simone G, Vitale RM, Di Fiore A, Pedone C, Scozzafava A, Montero JL, Winum JY, Supuran CT
* Carbonic anhydrase inhibitors: Hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX (412 visite)
J Med Chem (ISSN: 0022-2623, 1520-4804, 0022-2623print), 2006 Sep 7; 49(18): 5544-5551.
Impact Factor: 5.115
Dettagli Esporta in BibTeX Esporta in EndNote
Alterio V, Vitale RM, Monti SM, Pedone C, Scozzafava A, Cecchi A, De Simone G, Supuran CT
* Carbonic anhydrase inhibitors: X-ray and molecular modeling study for the interaction of a fluorescent antitumor sulfonamide with isozyme II and IX (370 visite)
J Am Chem Soc (ISSN: 0002-7863, 0002-2786, 1520-5126), 2006 Jun 28; 128(25): 8329-8335.
Impact Factor: 7.696
Dettagli Esporta in BibTeX Esporta in EndNote
Di Fiore A, Pedone C, D'Ambrosio K, Scozzafava A, De Simone G, Supuran CT
* Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II 'selective' inhibitor celecoxib (289 visite)
Bioorg Med Chem Lett Bioorganic And Medicinal Chemistry Letters (ISSN: 0960-894x), 2006 Jan 15; 16(2): 437-442.
Impact Factor: 2.538
Dettagli Esporta in BibTeX Esporta in EndNote
Menchise V, De Simone G, Alterio V, Di Fiore A, Pedone C, Scozzafava A, Supuran CT
* Carbonic anhydrase inhibitors: Stacking with Phe131 determines active site binding region of inhibitors as exemplified by the X-ray crystal structure of a membrane-impermeant antitumor sulfonamide complexed with isozyme II (440 visite)
J Med Chem (ISSN: 0022-2623, 1520-4804, 0022-2623print), 2005 Sep 8; 48(18): 5721-5727.
Impact Factor: 4.926
Dettagli Esporta in BibTeX Esporta in EndNote
De Simone G, Di Fiore A, Menchise V, Pedone C, Antel J, Casini A, Scozzafava A, Wurl M, Supuran CT
* Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies (302 visite)
Bioorg Med Chem Lett Bioorganic And Medicinal Chemistry Letters (ISSN: 0960-894x), 2005 May 2; 15(9): 2315-2320.
Impact Factor: 2.478
Dettagli Esporta in BibTeX Esporta in EndNote
Di Fiore A, De Simone G, Menchise V, Pedone C, Casini A, Scozzafava A, Supuran CT
* Carbonic anhydrase inhibitors: X-ray crystal structure of a benzenesulfonamide strong CA II and CA IX inhibitor bearing a pentafluorophenylaminothioureido tail in complex with isozyme II (430 visite)
Bioorg Med Chem Lett Bioorganic And Medicinal Chemistry Letters (ISSN: 0960-894x), 2005 Apr 1; 15(7): 1937-1942.
Impact Factor: 2.478
Dettagli Esporta in BibTeX Esporta in EndNote
Fonti R, Latella G, Caprilli R, Frieri G, Marcheggiano A, Sambuy Y
Carbonic anhydrase I reduction in colonic mucosa of patients with active ulcerative colitis (237 visite)
Digestive Diseases And Sciences (ISSN: 0163-2116), 1998; 43(9): 2086-2092.
Impact Factor: 1.972
Dettagli Esporta in BibTeX Esporta in EndNote
Soricelli A, Postiglione A, Cuocolo A, De Chiara S, Ruocco A, Brunetti A, Salvatore M, Ell PJ
EFFECT OF ADENOSINE ON CEREBRAL BLOOD-FLOW AS EVALUATED BY SINGLE-PHOTON EMISSION COMPUTED-TOMOGRAPHY IN NORMAL SUBJECTS AND IN PATIENTS WITH OCCLUSIVE CAROTID DISEASE - A COMPARISON WITH ACETAZOLAMIDE (236 visite)
Stroke (ISSN: 0039-2499), 1995 Sep; 26(9): 1572-1576.
Impact Factor: 4.323
Dettagli Esporta in BibTeX Esporta in EndNote
Mancini M, De Chiara S, Ferrara LA, Gallotta G, Postiglione A
TRANSCRANIAL DOPPLER EVALUATION OF CEREBROVASCULAR REACTIVITY TO ACETAZOLAMIDE IN NORMAL SUBJECTS (564 visite)
15th World Congress Angiology Rome, 1989; 20(4): 284-284.
Impact Factor: 0
Dettagli Esporta in BibTeX Esporta in EndNote
Testino G, Leone S, Fagoonee S, Del Bas JM, Rodriguez B, Puiggros F, Marine S, Rodriguez MA, Morina D, Armengol L, Caimari A, Arola L, Cimini FA, Barchetta I, Carotti S, Bertoccini L, Baroni MG, Vespasiani-gentilucci U, Cavallo MG, Morini S, Nelson JE, Roth CL, Wilson LA, Yates KP, Aouizerat B, Morgan-stevenson V, Whalen E, Hoofnagle A, Mason M, Gersuk V, Yeh MM, Kowdley KV, Lee SM, Jun DW, Cho YK, Jang KS, Kucukazman M, Ata N, Dal K, Yeniova AO, Kefeli A, Basyigit S, Aktas B, Akin KO, Agladioglu K, Ure OS, Topal F, Nazligul Y, Beyan E, Ertugrul DT, Catena C, Cosma C, Camozzi V, Plebani M, Ermani M, Sechi LA, Fallo F, Goto Y, Ray MB, Mendenhall CL, French SW, Gartside PS
Serum vitamin A deficiency and increased intrahepatic expression of cytokeratin antigen in alcoholic liver disease (485 visite)
Hepatology (ISSN: 1827-1669electronic, 0026-4806linking), 1988 Sep; 83120693611123109(5): 1019-1026.
Impact Factor: 0.913
Dettagli Esporta in BibTeX Esporta in EndNote
126 Records (124 escludendo Abstract e Conferenze).
Impact factor totale: 551.08 (545.965 escludendo Abstract e Conferenze).
Impact factor a 5 anni totale: 495.682 (490.178 escludendo Abstract e Conferenze).
Impact factor totale: 551.08 (545.965 escludendo Abstract e Conferenze).
Impact factor a 5 anni totale: 495.682 (490.178 escludendo Abstract e Conferenze).
Last modified by Ultima modifica di Marco Comerci on in data Sunday 12 July 2020, 13:15:03
410 views visite. Last view on Ultima visita in data Friday 07 May 2021, 1:59:24
ibb.cnr.it